<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431326</article-id><article-id pub-id-type="pmcid-ver">PMC12431326.1</article-id><article-id pub-id-type="pmcaid">12431326</article-id><article-id pub-id-type="pmcaiid">12431326</article-id><article-id pub-id-type="pmid">40938862</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0330841</article-id><article-id pub-id-type="publisher-id">PONE-D-25-21989</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>Natural antisense transcripts</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Chemical Characterization</subject><subj-group><subject>Binding Analysis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Physics</subject><subj-group><subject>Thermodynamics</subject><subj-group><subject>Free Energy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Biological Databases</subject><subj-group><subject>Protein Structure Databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Macromolecular Structure Analysis</subject><subj-group><subject>Protein Structure</subject><subj-group><subject>Protein Structure Databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Protein Structure</subject><subj-group><subject>Protein Structure Databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Identification and Analysis</subject><subj-group><subject>Genetic Networks</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Computer and Information Sciences</subject><subj-group><subject>Network Analysis</subject><subj-group><subject>Genetic Networks</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biochemical Simulations</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Biochemical Simulations</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Research and Development</subject><subj-group><subject>Drug Discovery</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Using systems biology and drug repositioning approaches to discover FDA-approved drugs candidates for endometriosis treatment</article-title><alt-title alt-title-type="running-head">Drug repositioning approaches to discover FDA-approved drugs candidates for endometriosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sanami</surname><given-names initials="S">Samira</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aghaamoo</surname><given-names initials="S">Shahrzad</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="S">Sajjad</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fazli</surname><given-names initials="A">Ali</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mansouri</surname><given-names initials="B">Bahareh</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nobre Oliveira</surname><given-names initials="JI">Jonas Ivan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-7122-5227</contrib-id><name name-style="western"><surname>Rahmanian</surname><given-names initials="M">Mojgan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Selvaraj</surname><given-names initials="C">Chandrabose</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>AMET University, INDIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* <email>dr_rahmanian@semums.ac.ir</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496058</issue-id><elocation-id>e0330841</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Sanami et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sanami et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0330841.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0330841.pdf"/><abstract><p>Endometriosis is characterized by the presence of endometrial tissue outside the uterine cavity. The administration of drugs designated for this condition has significant adverse effects, such as signs of estrogen insufficiency and suppression of ovulation. Considering this issue, this study aims to employ drugs repurposing approaches for the treatment of endometriosis. The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset was selected to assess the expression of genes involved in endometriosis, then differentially expressed genes (DEGs) were identified using the &#8220;Limma&#8221; package in R Studio. Functional and pathway enrichment analysis of 708 up-regulated and 414 down-regulated DEGs was performed using ShinyGO 0.81 and DAVID tools. the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was then used to build a protein-protein interaction (PPI) network of up-regulated DEGs, followed by Cytoscape software to identify hub genes. Vascular endothelial growth factor receptor 2 (VEGFR2) and interleukin-6 (IL-6) were identified as hub genes, assessments suggested that VEGFR2 may be a more promising possibility for druggability than IL-6. 16 FDA-approved drugs targeting VEGFR2 were identified, and molecular docking analysis indicated that ponatinib (&#8722;9.6 kcal/mol) had a more favorable binding energy than the co-crystal ligand (&#8722;9.2 kcal/mol). Moreover, molecular dynamics (MD) simulation analysis demonstrated considerable stability of the VEGFR2-ponatinib complex over a 100 nanoseconds (ns) timescale. The findings of this study indicate that ponatinib may provide considerable therapeutic promise for the treatment of endometriosis. Nevertheless, additional experimental investigations are required to evaluate its therapeutic efficacy.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100018764</institution-id><institution>Semnan University of Medical Sciences and Health Services</institution></institution-wrap></funding-source><award-id>4296</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-7122-5227</contrib-id><name name-style="western"><surname>Rahmanian</surname><given-names>Mojgan</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by a grant from Semnan University of Medical Sciences (Grant Number: 4296). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="3"/><page-count count="24"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its <xref rid="sec028" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its <xref rid="sec028" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Endometriosis impacts around 10% (190 million) of women and girls of reproductive age worldwide [<xref rid="pone.0330841.ref001" ref-type="bibr">1</xref>]. Endometriosis is a multifaceted and systemic clinical disease that can adversely affect women&#8217;s reproductive health and quality of life; it may commence with an individual&#8217;s first menstrual period and persist until menopause [<xref rid="pone.0330841.ref001" ref-type="bibr">1</xref>]. This condition&#8217;s pathological hallmark is abnormal endometrial tissue growth in the uterine outer regions [<xref rid="pone.0330841.ref002" ref-type="bibr">2</xref>]. The ovaries and pelvic peritoneum are the predominant locations for the development of endometriotic lesions. Endometriotic lesions may also occur in other locations, including the fallopian tubes, abdominal wall, intestines, cervix, bladder, and vagina [<xref rid="pone.0330841.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0330841.ref004" ref-type="bibr">4</xref>]. A comprehensive understanding of the pathogenesis of endometriosis may have significant clinical and therapeutic ramifications. Endometriosis has a complex pathophysiology that involves several pathways, including genetics, abnormal endocrine signaling, dysregulated cell growth and death, ectopic endometrial tissue, and altered immunity [<xref rid="pone.0330841.ref005" ref-type="bibr">5</xref>].</p><p>Endometriosis is a chronic condition that induces significant pain during menstruation, sexual intercourse, urination, or defecation. Endometriosis symptoms encompass chronic pelvic pain, bloating, nausea, fatigue, and occasionally depression, anxiety, and infertility. Symptoms of endometriosis encompass abdominal distension accompanied by infection, irregular uterine hemorrhage, vaginal discharge, pelvic pain, and discomfort in the lower abdomen. Additional symptoms of endometriosis encompass constipation accompanied by stomach or intestinal pain [<xref rid="pone.0330841.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0330841.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0330841.ref007" ref-type="bibr">7</xref>]. The sole definitive method for diagnosing endometriosis requires surgical intervention or laparoscopy, leading to a latency period of 7&#8211;11 years from the onset of symptoms to a conclusive diagnosis [<xref rid="pone.0330841.ref008" ref-type="bibr">8</xref>], and entails an increased risk of disease progression during that time [<xref rid="pone.0330841.ref009" ref-type="bibr">9</xref>]. In recent years, noninvasive imaging techniques, particularly transvaginal ultrasonography and magnetic resonance imaging (MRI), have improved diagnostic accuracy for endometriosis, enabling the staging and classification of different types of the endometriosis without the need for surgical procedures [<xref rid="pone.0330841.ref010" ref-type="bibr">10</xref>&#8211;<xref rid="pone.0330841.ref012" ref-type="bibr">12</xref>].</p><p>Drug repurposing denotes the identification of novel therapeutic applications for established medications to improve their efficacy and optimize their use [<xref rid="pone.0330841.ref013" ref-type="bibr">13</xref>]. The advantages of Food and Drug Administration (FDA)-approved drug repositioning are numerous, and since many preclinical and clinical trials have already been carried out on these drugs, their use saves time and cost as compared to developing de novo drugs [<xref rid="pone.0330841.ref014" ref-type="bibr">14</xref>]. The primary hurdles involve identifying drug target proteins (receptors) associated with diseases and discovering pharmacological agents (small molecules) that can mitigate these disorders through contact with the target proteins. The identification of hub genes via bioinformatics has become an effective method for discovering prospective biomarkers and therapeutic targets [<xref rid="pone.0330841.ref015" ref-type="bibr">15</xref>]. Transcriptomics analysis is a prominent strategy for discovering genetic biomarkers. Proteins produced by genomic biomarkers are regarded as key receptors [<xref rid="pone.0330841.ref016" ref-type="bibr">16</xref>&#8211;<xref rid="pone.0330841.ref018" ref-type="bibr">18</xref>].</p><p>Endometriosis treatment options currently include drugs, surgical procedures, surgery combined with drugs, and assisted reproductive technology (ART). While surgery remains an appropriate method for endometriosis-related pelvic pain, its efficacy is undermined by limitations, including a 40&#8722;50% recurrence rate after surgery [<xref rid="pone.0330841.ref019" ref-type="bibr">19</xref>]. Administering drugs to reduce related symptoms is preferable for patients without surgical indications. First-line pharmacological treatments comprise non-steroidal anti-inflammatory drugs (NSAIDs), progestins, and oral contraceptives (OCs). Second-line drugs comprise gonadotropin-releasing hormone agonists (GnRH-a) and the levonorgestrel intrauterine delivery method. Nonetheless, the administration of the mentioned drugs, including GnRH-a, is associated with significant adverse effects, such as symptoms of estrogen insufficiency and inhibition of ovulation. Consequently, it is inappropriate for prolonged usage, particularly for individuals with reproductive requirements [<xref rid="pone.0330841.ref020" ref-type="bibr">20</xref>]. Given these limitations, there is an urgent need for identification of new biological targets and drugs. Zhang <italic toggle="yes">et al</italic>.&#8216;s study indicated that the primary biological targets of tanshinone IIA, the active component of Chinese medicine Danshen (<italic toggle="yes">Salvia miltiorrhiza</italic> Bge.), for endometriosis treatment are vascular endothelial growth factor A (VEGFA), matrix metalloproteinase 9 (MMP-9), estrogen receptor-1 (ESR1), intercellular adhesion molecule (ICAM)&#8209;1, and interleukin-2 (IL&#8209;2), which exert pathological effects on the adhesion, invasion, and angiogenesis of ectopic endometrial tissue within the pelvic and abdominal cavities in endometriosis [<xref rid="pone.0330841.ref021" ref-type="bibr">21</xref>].</p><p>The current study also aimed to find hub genes in endometriosis, identify and evaluate FDA-approved drugs that target the proteins encoded by these genes. In the present study, we first downloaded <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset from the Gene Expression Omnibus (GEO). After pre-processing and normalizing the data by the &#8220;Limma&#8221; package in R Studio, we identified DEGs. Next, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed by the ShinyGO 0.81 and DAVID tools, respectively. PPI network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and Cytoscape software was used to identify cluster modules and hub genes. Then, target transcription factors (TFs) and microRNAs (miRNAs) of selected hub genes were predicted by NetworkAnalyst tool. Subsequently, the druggability of hub genes and their associated TFs was assessed using the Drug-Gene Interaction Database (DGIdb 5.0). The DrugBank database was searched to find FDA-approved drugs that were ligands for the target protein, and then their virtual screening was performed using PyRx 0.8 software. Finally, molecular dynamics (MD) simulation of the target protein and docked complexes were performed by the Assisted Model Building with Energy Refinement (AMBER) 18 program.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Data collection</title><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset was obtained from the GEO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/geo/(database" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/(database</ext-link> (accessed on 3 February 2025) [<xref rid="pone.0330841.ref022" ref-type="bibr">22</xref>]. This gene expression profile was generated using the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GPL6480">GPL6480</ext-link> (Agilent-014850 Whole Human Genome Microarray 4x44K G4112F) platform and derived from a study conducted by Bhat <italic toggle="yes">et al</italic> [<xref rid="pone.0330841.ref023" ref-type="bibr">23</xref>]. The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset contains 9 human endometrial tissue samples from each of the four groups: fertile women with endometriosis (FE), fertile women without endometriosis (FC), infertile women with endometriosis (IE), and infertile women without endometriosis (IC).</p></sec><sec id="sec004"><title>Identification of differentially expressed genes (DEGs)</title><p>Using &#8220;Limma&#8221; package [<xref rid="pone.0330841.ref024" ref-type="bibr">24</xref>] in R Studio [<xref rid="pone.0330841.ref025" ref-type="bibr">25</xref>], we identified differentially expressed genes (DEGs) between the FE and FC groups, as well as between the IE and IC groups, in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset. DEGs were selected based on |log2 fold change (FC)|&#8201;&gt;&#8201;1 and adjusted P-value&#8201;&lt;&#8201;0.05. The &#8220;ggplot2&#8221; package in RStudio was used to create the volcano plot [<xref rid="pone.0330841.ref026" ref-type="bibr">26</xref>]. The &#8220;Venn&#8221; package in R Studio was used to screen for common up- and down-regulated DEGs in the FE and IE groups [<xref rid="pone.0330841.ref027" ref-type="bibr">27</xref>].</p></sec><sec id="sec005"><title>Functional and pathway enrichment analysis of DEGs</title><p>GO functional analysis and KEGG pathway assessment of common up- and down-regulated DEGs between the FE and IE groups were conducted using ShinyGO 0.81 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinformatics.sdstate.edu/go/" ext-link-type="uri">https://bioinformatics.sdstate.edu/go/</ext-link>) (accessed on 5 February 2025) [<xref rid="pone.0330841.ref028" ref-type="bibr">28</xref>] and DAVID (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://davidbioinformatics.nih.gov/" ext-link-type="uri">https://davidbioinformatics.nih.gov/</ext-link>) (accessed on 5 February 2025) [<xref rid="pone.0330841.ref029" ref-type="bibr">29</xref>], respectively. The GO terms are divided into three categories: biological processe (BP), molecular function (MF), and cellular component (CC). In the analysis conducted in the ShinyGO 0.81 tool, False Discovery Rate (FDR) value of 0.05 was used as the significance cutoff, as well as, the significance level in the analysis conducted in the DAVID tool was set to P- value&#8201;&lt;&#8201;0.05. The ShinyGO 0.81 tool used an FDR value of 0.05 as the significance cutoff, while the DAVID tool used a P-value&#8201;&lt;&#8201;0.05 as the significance level.</p></sec><sec id="sec006"><title>PPI network analysis and hub gene identification</title><p>We used the STRING (version: 12.0) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://string-db.org/" ext-link-type="uri">https://string-db.org/</ext-link>) (accessed on 6 February 2025) to develop a protein-protein interaction (PPI) network of shared up-regulated DEGs in the FE and IE groups. A minimum required interaction score of 0.700 (high confidence) was set for the generation of this interaction network. The database currently comprises 12535 organisms, 59.3 million proteins, and more than 20 billion documented interactions [<xref rid="pone.0330841.ref030" ref-type="bibr">30</xref>]. We then used the Cytoscape software (version 3.10.3) to further analyze and visualize the PPI network. Cytoscape is an open-source software platform designed for visualizing intricate networks and merging them with many types of attribute data [<xref rid="pone.0330841.ref031" ref-type="bibr">31</xref>]. We next used the CytoHubba plugin [<xref rid="pone.0330841.ref032" ref-type="bibr">32</xref>] to identify hub genes based on five topological analysis algorithms: Betweenness [<xref rid="pone.0330841.ref033" ref-type="bibr">33</xref>], BottleNeck [<xref rid="pone.0330841.ref034" ref-type="bibr">34</xref>], Closeness [<xref rid="pone.0330841.ref035" ref-type="bibr">35</xref>], Degree [<xref rid="pone.0330841.ref036" ref-type="bibr">36</xref>], and Stress [<xref rid="pone.0330841.ref037" ref-type="bibr">37</xref>]. The top 10 genes were chosen based on each method, and the shared genes among these five algorithms were considered as the final hub genes.</p></sec><sec id="sec007"><title>Regulatory network analysis of hub genes</title><p>The NetworkAnalyst tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.networkanalyst.ca/" ext-link-type="uri">https://www.networkanalyst.ca/</ext-link>) (accessed on 7 February 2025) was used to map interactions among important transcriptional regulatory transcription factors (TFs) and post-transcriptional regulatory microRNAs (miRNAs) with hub genes [<xref rid="pone.0330841.ref038" ref-type="bibr">38</xref>&#8211;<xref rid="pone.0330841.ref040" ref-type="bibr">40</xref>]. The JASPAR [<xref rid="pone.0330841.ref041" ref-type="bibr">41</xref>] and miRTarBase v9.0 [<xref rid="pone.0330841.ref042" ref-type="bibr">42</xref>] databases were used to generate the TFs-hub genes network and the miRNAs-hub genes network, respectively.</p></sec><sec id="sec008"><title>Identification of druggable genes</title><p>The DGIdb 5.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dgidb.org/" ext-link-type="uri">https://dgidb.org/</ext-link>) (accessed on 8 February 2025) was used to analyze the druggability of hub genes and their related TFs identified in our study. The DGIdb provides information regarding drug-gene interactions and druggability sourced from publications, databases, and various online resources [<xref rid="pone.0330841.ref043" ref-type="bibr">43</xref>]. This database categorizes genes as potentially druggable based on their presence in selected pathways, molecular functions, and gene families from the Gene Ontology, the Human Protein Atlas, IDG, &#8220;druggable genome&#8221; lists from Hopkins and Groom (2002) [<xref rid="pone.0330841.ref044" ref-type="bibr">44</xref>] and Russ and Lampel (2005) [<xref rid="pone.0330841.ref045" ref-type="bibr">45</xref>].</p></sec><sec id="sec009"><title>Retrieval and preparation of protein target structure and FDA-approved drugs</title><p>The target protein&#8217;s X-ray crystal structure was obtained from the RCSB Protein Data Bank (PDB) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/" ext-link-type="uri">https://www.rcsb.org/</ext-link>) (accessed on 9 February 2025) in PDB format (Supplementary <xref rid="pone.0330841.s013" ref-type="supplementary-material">S1 File</xref>) [<xref rid="pone.0330841.ref046" ref-type="bibr">46</xref>]. We removed all co-crystallized ligands, heteroatoms, and associated crystal water molecules from the parent structure using the UCSF Chimera software (version 1.10.2) [<xref rid="pone.0330841.ref047" ref-type="bibr">47</xref>] to ensure that pre-bound molecules did not influence the binding affinity of the predicted drugs. To fill in the missing residues in the target protein&#8217;s crystal structure, homology modeling was performed using SWISS-MODEL software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://swissmodel.expasy.org/" ext-link-type="uri">https://swissmodel.expasy.org/</ext-link>) (accessed on 9 February 2025) and the parent sequence as a template [<xref rid="pone.0330841.ref048" ref-type="bibr">48</xref>]. The pKa values of the ionizable groups in the protein were ascertained using PROPKA version 3.1, facilitating the optimization of the hydrogen bond network at pH 7.4 [<xref rid="pone.0330841.ref049" ref-type="bibr">49</xref>]. Energy minimization was done using UCSF Chimera software (version 1.10.2) with default parameters such as steepest descent steps of 1000, steepest descent step size of 0.02 &#197;, conjugate step gradient of 10, conjugate steps of 0.02 &#197;, and update interval of 100. The DrugBank database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://go.drugbank.com/" ext-link-type="uri">https://go.drugbank.com/</ext-link>) (accessed on 10 February 2025) [<xref rid="pone.0330841.ref050" ref-type="bibr">50</xref>] was searched to identify the FDA-approved drugs that formed ligands for the target protein during the docking analysis. Among the identified drugs, those with inhibitory activity and available structures were retrieved from the PubChem database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) (accessed on 10 February 2025) in structure-data file (SDF) format [<xref rid="pone.0330841.ref051" ref-type="bibr">51</xref>].</p></sec><sec id="sec010"><title>Molecular docking-based virtual screening</title><p>Molecular docking-based virtual screening was conducted to identify drugs with high binding affinity for the target protein. The AutoDock Vina Wizard [<xref rid="pone.0330841.ref052" ref-type="bibr">52</xref>] in PyRx 0.8 software was utilized for screening [<xref rid="pone.0330841.ref053" ref-type="bibr">53</xref>]. The appropriate file formats for the receptor and ligand for molecular docking were generated in PDBQT format using PyRx 0.8 software. Active sites were defined as regions within the target protein structure that were less than 5 &#197; distant from the co-cocrystal ligands. The molecular docking analysis was conducted using dimensions of X&#8201;=&#8201;29.3683 &#197;, Y&#8201;=&#8201;23.2777 &#197;, and Z&#8201;=&#8201;17.8267 &#197;, respectively, and the center coordinates for X, Y, and Z were set as &#8722;1.5459, 35.5985, and 14.8893, respectively. The grid box contained all of the residues required for binding, including Leu35, Gly36, Arg37, Gly38, Gly41, Val43, Ala61, Lys63, Glu80, Ile83, Leu84, Ile87, Val93, Val94, Val111, Glu112, Phe113, Cys114, Leu164, His171, Leu180, Ile189, Cys190, and Asp191. To validate the docking method, we also performed redocking of the co-crystal ligand with the target protein. Following docking, hit drugs candidates were chosen based on binding affinity scores.</p></sec><sec id="sec011"><title>Interaction analysis in docked complexes</title><p>The analysis of protein-ligand interactions is a crucial component of the drug discovery process, since it elucidates the molecular mechanisms that may account for the efficacy or ineffectiveness of specific drugs [<xref rid="pone.0330841.ref054" ref-type="bibr">54</xref>]. In this study, the ProLIF package was used to visualize docking results and analyze interactions between receptor protein and ligand residues in the docked complexes. ProLIF (Protein-Ligand Interaction Fingerprints) is a Python utility for generating interaction fingerprints for molecular complexes. These fingerprints are vector representations of molecular interactions in three dimensions. This occurs frequently between proteins and ligands [<xref rid="pone.0330841.ref055" ref-type="bibr">55</xref>].</p></sec><sec id="sec012"><title>Molecular dynamics simulation</title><p>The dynamic behavior of unbound receptor and docked complexes was investigated using MD simulation. The simulation protocol was executed with the AMBER 18 program [<xref rid="pone.0330841.ref056" ref-type="bibr">56</xref>]. The primary coordinates were derived from the unbound receptors, docked complexes, and topology files were prepared utilizing the tLEAP interface of AMBER 18. System solvation was performed with three-point transferable intermolecular potential (TIP3P) water, and the force fields used for computations were General Amber Force Field (GAFF) [<xref rid="pone.0330841.ref057" ref-type="bibr">57</xref>] and ff99SB. To neutralize the system&#8217;s overall charge, sodium counter-ions were introduced. To eliminate steric clashes, the docked protein complex underwent minimization through 1500 steepest descent and 1000 conjugate gradient steps. Langevin dynamics were utilized for system heating over 10 picoseconds (ps) [<xref rid="pone.0330841.ref058" ref-type="bibr">58</xref>], followed by 100&#8201;ps of equilibration in the canonical (NVT) ensemble. During the production run, hydrogen bonds were constrained using the SHAKE algorithm [<xref rid="pone.0330841.ref059" ref-type="bibr">59</xref>]. The temperature of the system was incrementally raised from 0 to 300&#8201;K over 200&#8201;ps at constant volume, after which the system was equilibrated at constant pressure. The production run lasted for a total of 100 nanoseconds (ns). The final MD trajectories for unbound receptor and docked complexes was examined. The analysis includes generation root mean square deviation (RMSD), root mean square fuctuation (RMSF), radius of gyration (Rg), and solvent accessible surface area (SASA) values for free receptor and docked complexes.</p></sec><sec id="sec013"><title>MM-PBSA/GBSA analysis</title><p>The molecular mechanics Poisson&#8211;Boltzmann surface area (MM-PBSA) and molecular mechanics generalized Born surface area (MM-GBSA) methods were employed to compute the binding free energies of the docked complexes [<xref rid="pone.0330841.ref060" ref-type="bibr">60</xref>]. A total of 450 frames each after 0.2 ns were extracted from the complete MD trajectory and analyzed using the MM-PBSA computation via the MMPBSA.py module [<xref rid="pone.0330841.ref061" ref-type="bibr">61</xref>] of AMBER18. To determine the binding free energies (&#9651;G<sub>bind</sub>) values, the following equation was used:</p><disp-formula id="pone.0330841.e001"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.e001g" position="anchor" orientation="portrait" xlink:href="pone.0330841.e001.jpg"/><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mtext>&#160;</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>+</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</mml:mtext></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula><p>&#916;G<sub>complex</sub> represents the total free energy of the protein-ligand complex, while &#916;G<sub>receptor</sub> and &#916;G<sub>ligand</sub> indicate the total free energies of the separated protein and ligand in solvent, respectively.</p><disp-formula id="pone.0330841.e002"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.e002g" position="anchor" orientation="portrait" xlink:href="pone.0330841.e002.jpg"/><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>+</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</mml:mtext></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula><p>T denotes the temperature, while S signifies the entropy contribution to ligand binding, determined by established approximations. The gas phase energy (E<sub>gas</sub>) is commonly derived from the force field&#8217;s MM. It encompasses contributions from internal energy, electrostatic interactions, and van der Waals interaction energies as follows:</p><disp-formula id="pone.0330841.e003"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.e003g" position="anchor" orientation="portrait" xlink:href="pone.0330841.e003.jpg"/><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>+</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mrow><mml:mi>v</mml:mi><mml:mi>d</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</mml:mtext></mml:mrow></mml:math></alternatives><label>(3)</label></disp-formula><p>The &#916;G<sub>solv</sub> term is computed via an implicit solvent model and divided into electrostatic and non-polar components.</p><disp-formula id="pone.0330841.e004"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.e004g" position="anchor" orientation="portrait" xlink:href="pone.0330841.e004.jpg"/><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;</mml:mtext><mml:mo>+</mml:mo><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mrow><mml:mi>&#916;</mml:mi><mml:mi>G</mml:mi><mml:mtext>&#160;</mml:mtext></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mtext>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</mml:mtext></mml:mrow></mml:math></alternatives><label>(4)</label></disp-formula></sec><sec id="sec014"><title>Ethics statement</title><p>The ethical committee of Semnan University of Medical Sciences approved this study with the number: IR.SEMUMS.REC.1403.248.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>Identification of differentially expressed genes (DEGs)</title><p>All four groups of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset underwent normalization, and a box plot was generated to illustrate the data distribution before and after to normalization (<xref rid="pone.0330841.g001" ref-type="fig">Fig 1A</xref>, <xref rid="pone.0330841.g001" ref-type="fig">B</xref>). A total of 4764 DEGs were identified between the FE and FC groups, with 2618 up-regulated and 2146 down-regulated. On the other hand, 9736 DEGs were found between the IE and IC groups, comprising 4266 up-regulated and 5470 down-regulated DEGs (Supplementary <xref rid="pone.0330841.s001" ref-type="supplementary-material">S1 Table</xref>). The DEGs between the FE and FC groups, as well as between the IE and IC groups, were depicted using a volcano plot (<xref rid="pone.0330841.g001" ref-type="fig">Fig 1C</xref>, <xref rid="pone.0330841.g001" ref-type="fig">D</xref>). According to the Venn diagram, 708 up-regulated and 414 down-regulated DEGs were found to be common in both FE and IE (<xref rid="pone.0330841.g001" ref-type="fig">Fig 1E</xref>, <xref rid="pone.0330841.g001" ref-type="fig">F</xref>).</p><fig position="float" id="pone.0330841.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g001</object-id><label>Fig 1</label><caption><title>DEGs analysis for the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset.</title><p><bold>(A)</bold> Box plot of the expression data before and (B after normalization. <bold>(C)</bold> Volcano plot of DEG between FE and FC groups. <bold>(D)</bold> Volcano plot of DEG between IE and IC groups. <bold>(E)</bold> The Venn diagram of the overlapping up-regulated DEGs in FE and IE. <bold>(F)</bold> The Venn diagram of the overlapping down-regulated DEGs in FE and IE.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g001.jpg"/></fig></sec><sec id="sec017"><title>Functional and pathway enrichment analysis of DEGs</title><p>The ShinyGO 0.81 tool provided 355 GO items for common up-regulated DEGs between the FE and IE groups, including 269 BP items (Supplementary <xref rid="pone.0330841.s002" ref-type="supplementary-material">S2 Table</xref>), 42 MF items (Supplementary <xref rid="pone.0330841.s003" ref-type="supplementary-material">S3 Table</xref>), and 44 CC items (Supplementary <xref rid="pone.0330841.s004" ref-type="supplementary-material">S4 Table</xref>). Similarly, 405 GO items for common down-regulated DEGs between the FE and IE groups were obtained, comprising 294 BP (Supplementary <xref rid="pone.0330841.s005" ref-type="supplementary-material">S5 Table</xref>), 44 MF (Supplementary <xref rid="pone.0330841.s006" ref-type="supplementary-material">S6 Table</xref>), and 67 CC (Supplementary <xref rid="pone.0330841.s007" ref-type="supplementary-material">S7 Table</xref>) items. <xref rid="pone.0330841.g002" ref-type="fig">Fig 2</xref> illustrates the 10 most significant functional enrichment analyses of BP, CC, and MF catalogs for up- and down-regulated DEGs. The DAVID tool identified up-regulated DEGs in 18 KEGG enrichment pathways, with 10 being significant (P-value&#8201;&lt;&#8201;0.05) (Supplementary <xref rid="pone.0330841.s008" ref-type="supplementary-material">S8 Table</xref>). Down-regulated DEGs were associated in 31 KEGG enrichment pathways, 21 of which were significant (Supplementary <xref rid="pone.0330841.s009" ref-type="supplementary-material">S9 Table</xref>).</p><fig position="float" id="pone.0330841.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g002</object-id><label>Fig 2</label><caption><title>The lollipop charts of the 10 most significant functional enrichment analyses of GO for shared DEGs between the FE and IE groups.</title><p><bold>(A)</bold> BP corresponding to common up-regulated DEGs, <bold>(B)</bold> MF corresponding to common up-regulated DEGs, <bold>(C)</bold> CC corresponding to common up-regulated DEGs, <bold>(D)</bold> BP corresponding to common down-regulated DEGs, <bold>(E)</bold> MF corresponding to common down-regulated DEGs, <bold>(F)</bold> CC corresponding to common down-regulated DEGs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g002.jpg"/></fig></sec><sec id="sec018"><title>PPI network analysis and hub gene identification</title><p>The PPI network of shared up-regulated DEGs in the FE and IE groups, consisting of 614 nodes and 236 edges, was generated using STRING (<xref rid="pone.0330841.g003" ref-type="fig">Fig 3</xref>). To enhance clarity, we removed isolated genes that lacked interactions with other genes. Supplementary <xref rid="pone.0330841.s010" ref-type="supplementary-material">S10 Table</xref> and <xref rid="pone.0330841.g004" ref-type="fig">Fig 4</xref> indicate the top 10 genes identified through the five methods provided by Cytoscape&#8217;s CytoHubba plugin. The Venn diagram indicated a presence of two common genes, namely IL-6 and Kinase Insert Domain Receptor (KDR), among the genes identified by all five approaches (<xref rid="pone.0330841.g005" ref-type="fig">Fig 5</xref>). Consequently, we selected these genes as potential hub gene candidates.</p><fig position="float" id="pone.0330841.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g003</object-id><label>Fig 3</label><caption><title>The PPI network comprising shared up-regulated DEGs in the FE and IE groups.</title><p>The network comprises 614 nodes and 236 edges. Each node signifies a protein, while each edge denotes a protein-protein association.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g003.jpg"/></fig><fig position="float" id="pone.0330841.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g004</object-id><label>Fig 4</label><caption><title>The top 10 genes identified using the five approaches given by the Cytoscape&#8217;s CytoHubba plugin(A) The top 10 genes identified using Betweenness method.</title><p><bold>(B)</bold> The top 10 genes identified using BottleNeck method. <bold>(C)</bold> The top 10 genes identified using Closeness method. <bold>(D)</bold> The top 10 genes identified using Degree method. <bold>(E)</bold> The top 10 genes identified using Stress method. The colors represent high (red) to low (yellow) scores.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g004.jpg"/></fig><fig position="float" id="pone.0330841.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g005</object-id><label>Fig 5</label><caption><title>The Venn diagram reveals the presence of two common hub genes, IL-6 and KDR, resulting from the intersection of the top 10 genes identified using the five approaches given by the Cytoscape&#8217;s CytoHubba plugin.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g005.jpg"/></fig></sec><sec id="sec019"><title>Regulatory network analysis of hub genes</title><p>The miRNAs/TFs-hub genes network was constructed using the NetworkAnalyst tool. The miRNAs/TFs-IL6 network comprises 7 TFs and 33 miRNAs (Supplementary <xref rid="pone.0330841.s011" ref-type="supplementary-material">S11 Table</xref>), while the miRNAs/TFs-KDR network consists of 9 TFs and 22 miRNAs (Supplementary <xref rid="pone.0330841.s012" ref-type="supplementary-material">S12 Table</xref>). In the network, hsa-miR-155-5p, hsa-miR-335-5p, hsa-miR-199a-3p, FOXC1, and STAT3 interacted with both hub genes (<xref rid="pone.0330841.g006" ref-type="fig">Fig 6</xref>).</p><fig position="float" id="pone.0330841.g006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g006</object-id><label>Fig 6</label><caption><title>The miRNAs/TFs-hub genes network.</title><p>The red circle, green diamond, and purple circle indicate hub genes, miRNAs, and TFs, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g006.jpg"/></fig></sec><sec id="sec020"><title>Identification of druggable genes</title><p>The DGIdb 5.0 revealed that among the hub genes and their corresponding TFs, IL-6, KDR, and STAT3 had druggability potential (<xref rid="pone.0330841.t001" ref-type="table">Table 1</xref>). We chose the KDR (kinase insert domain receptor) gene for further investigation because it belongs to the kinase family, is located on the outside of the plasma membrane, and exists in both druggable genome lists from Hopkins and Groom (2002) and Russ and Lampel (2005). Synonyms for the KDR gene include vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR, fetal liver kinase 1 (FLK1), and CD309, with VEGFR2 utilized in this article henceforth.</p><table-wrap position="float" id="pone.0330841.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.t001</object-id><label>Table 1</label><caption><title>Results of the evaluation of the druggability potential of hub genes and their related TFs.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.t001g" position="float" orientation="portrait" xlink:href="pone.0330841.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">gene</th><th align="left" rowspan="1" colspan="1">category</th><th align="left" rowspan="1" colspan="1">sources</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>IL6</bold>
</td><td align="left" rowspan="1" colspan="1">DRUG RESISTANCE</td><td align="left" rowspan="1" colspan="1">CIViC</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DRUGGABLE GENOME</td><td align="left" rowspan="1" colspan="1">HingoraniCasas</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GROWTH FACTOR</td><td align="left" rowspan="1" colspan="1">GO</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>FOXC1</bold>
</td><td align="left" rowspan="1" colspan="1">TRANSCRIPTION FACTOR</td><td align="left" rowspan="1" colspan="1">Pharos</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>STAT3</bold>
</td><td align="left" rowspan="1" colspan="1">CLINICALLY ACTIONABLE</td><td align="left" rowspan="1" colspan="1">CarisMolecularIntelligence, FoundationOneGenes, Oncomine, Tempus</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DRUGGABLE GENOME</td><td align="left" rowspan="1" colspan="1">HingoraniCasas</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">KINASE</td><td align="left" rowspan="1" colspan="1">Pharos</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NUCLEAR HORMONE RECEPTOR</td><td align="left" rowspan="1" colspan="1">GO</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TRANSCRIPTION FACTOR COMPLEX</td><td align="left" rowspan="1" colspan="1">GO</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TUMOR SUPPRESSOR</td><td align="left" rowspan="1" colspan="1">GO</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>KDR</bold>
</td><td align="left" rowspan="1" colspan="1">CLINICALLY ACTIONABLE</td><td align="left" rowspan="1" colspan="1">CarisMolecularIntelligence, FoundationOneGenes, MskImpact, Oncomine, Tempus</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">DRUGGABLE GENOME</td><td align="left" rowspan="1" colspan="1">HingoraniCasas, HopkinsGroom, RussLampel</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">EXTERNAL SIDE OF PLASMA MEMBRANE</td><td align="left" rowspan="1" colspan="1">GO</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">KINASE</td><td align="left" rowspan="1" colspan="1">HopkinsGroom, Pharos, dGene</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TYROSINE KINASE</td><td align="left" rowspan="1" colspan="1">GO, dGene</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec021"><title>Retrieval and preparation of protein target structure and FDA-approved drugs</title><p>The PDB format structure of the human VEGFR2 protein (ID: 1YWN, resolution: 1.71 &#197;) in complex with 4-amino-furo[2,3-d] pyrimidine (also known as leukaemia inhibitory factor (LIF)) was downloaded from RCSB PDB, and the preparation process was conducted on it (Supplementary S13 File). A collection of 16 FDA-approved drugs in SDF format was obtained from the DrugBank database (Supplementary <xref rid="pone.0330841.s015" ref-type="supplementary-material">S14 File</xref>). This library included a list of drugs that possessed both an available structure and inhibitory characteristics (<xref rid="pone.0330841.t002" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="pone.0330841.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.t002</object-id><label>Table 2</label><caption><title>A list of FDA-approved drugs targeting human VEGFR2, with their binding affinity values (kcal/mol) against human VEGFR2.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.t002g" position="float" orientation="portrait" xlink:href="pone.0330841.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">NO.</th><th align="left" rowspan="1" colspan="1">Drugbank ID</th><th align="left" rowspan="1" colspan="1">Chemical Formula</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Binding Affinity (kcal/mol)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">DB09079</td><td align="left" rowspan="1" colspan="1">C<sub>31</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub></td><td align="left" rowspan="1" colspan="1">Nintedanib</td><td align="left" rowspan="1" colspan="1">&#8722;7.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="left" rowspan="1" colspan="1">DB06589</td><td align="left" rowspan="1" colspan="1">C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>S</td><td align="left" rowspan="1" colspan="1">Pazopanib</td><td align="left" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="left" rowspan="1" colspan="1">DB08896</td><td align="left" rowspan="1" colspan="1">C<sub>21</sub>H<sub>15</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>3</sub></td><td align="left" rowspan="1" colspan="1">Regorafenib</td><td align="left" rowspan="1" colspan="1">&#8722;9.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">DB14840</td><td align="left" rowspan="1" colspan="1">C<sub>24</sub>H<sub>21</sub>BrFN<sub>5</sub>O<sub>2</sub></td><td align="left" rowspan="1" colspan="1">Ripretinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="left" rowspan="1" colspan="1">DB05294</td><td align="left" rowspan="1" colspan="1">C<sub>22</sub>H<sub>24</sub>BrFN<sub>4</sub>O<sub>2</sub></td><td align="left" rowspan="1" colspan="1">Vandetanib</td><td align="left" rowspan="1" colspan="1">&#8722;7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td align="left" rowspan="1" colspan="1">DB06626</td><td align="left" rowspan="1" colspan="1">C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>OS</td><td align="left" rowspan="1" colspan="1">Axitinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td align="left" rowspan="1" colspan="1">DB12010</td><td align="left" rowspan="1" colspan="1">C<sub>23</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>9</sub>P</td><td align="left" rowspan="1" colspan="1">Fostamatinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="left" rowspan="1" colspan="1">DB11679</td><td align="left" rowspan="1" colspan="1">C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub></td><td align="left" rowspan="1" colspan="1">Fruquintinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>9</bold>
</td><td align="left" rowspan="1" colspan="1">DB09078</td><td align="left" rowspan="1" colspan="1">C<sub>21</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>4</sub></td><td align="left" rowspan="1" colspan="1">Lenvatinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td><td align="left" rowspan="1" colspan="1">DB06595</td><td align="left" rowspan="1" colspan="1">C<sub>35</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub></td><td align="left" rowspan="1" colspan="1">Midostaurin</td><td align="left" rowspan="1" colspan="1">&#8722;8.4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>11</bold>
</td><td align="left" rowspan="1" colspan="1">DB11828</td><td align="left" rowspan="1" colspan="1">C<sub>30</sub>H<sub>29</sub>ClN<sub>6</sub>O<sub>3</sub></td><td align="left" rowspan="1" colspan="1">Neratinib</td><td align="left" rowspan="1" colspan="1">&#8722;8.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="left" rowspan="1" colspan="1">DB08901</td><td align="left" rowspan="1" colspan="1">C<sub>29</sub>H<sub>27</sub>F<sub>3</sub>N<sub>6</sub>O</td><td align="left" rowspan="1" colspan="1">Ponatinib</td><td align="left" rowspan="1" colspan="1">&#8722;9.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="left" rowspan="1" colspan="1">DB15822</td><td align="left" rowspan="1" colspan="1">C<sub>27</sub>H<sub>32</sub>FN<sub>9</sub>O<sub>2</sub></td><td align="left" rowspan="1" colspan="1">Pralsetinib</td><td align="left" rowspan="1" colspan="1">&#8722;9.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>14</bold>
</td><td align="left" rowspan="1" colspan="1">DB00398</td><td align="left" rowspan="1" colspan="1">C<sub>21</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub></td><td align="left" rowspan="1" colspan="1">Sorafenib</td><td align="left" rowspan="1" colspan="1">&#8722;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="left" rowspan="1" colspan="1">DB01268</td><td align="left" rowspan="1" colspan="1">C<sub>22</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>2</sub></td><td align="left" rowspan="1" colspan="1">Sunitinib</td><td align="left" rowspan="1" colspan="1">&#8722;7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="left" rowspan="1" colspan="1">DB11800</td><td align="left" rowspan="1" colspan="1">C<sub>22</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>5</sub></td><td align="left" rowspan="1" colspan="1">Tivozanib</td><td align="left" rowspan="1" colspan="1">&#8722;8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>17</bold>
</td><td align="left" rowspan="1" colspan="1">DB04727</td><td align="left" rowspan="1" colspan="1">C<sub>27</sub>H<sub>19</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub></td><td align="left" rowspan="1" colspan="1">LIF</td><td align="left" rowspan="1" colspan="1">&#8722;9.2</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec022"><title>Molecular docking-based virtual screening</title><p>The molecular docking analysis, which used FDA-approved drugs as ligands targeting human VEGFR2, revealed valuable insights on molecular interactions. Molecular docking was carried out using a grid box including all of the binding residues, including Leu35, Gly36, Arg37, Gly38, Gly41, Val43, Ala61, Lys63, Glu80, Ile83, Leu84, Ile87, Val93, Val94, Val111, Glu112, Phe113, Cys114, Leu164, His171, Leu180, Ile189, Cys190, and Asp191. The results of molecular binding analysis revealed that 16 FDA-approved drugs had binding affinities ranging from &#8722;7.6 to &#8722;9.6 kcal/mol, with only one drug (ponatinib) having a greater binding affinity than the co-crystal ligand (LIF) and being chosen for further study. <xref rid="pone.0330841.t002" ref-type="table">Table 2</xref> presents the binding affinities of the FDA-approved drugs targeting human VEGFR2.</p></sec><sec id="sec023"><title>Interaction analysis in docked complexes</title><p>The binding orientation and interaction of ponatinib and LIF within the binding pocket of human VEGFR2 were predicted using the UCSF Chimera software and ProLIF package, respectively. <xref rid="pone.0330841.g007" ref-type="fig">Fig 7A</xref> illustrates that ponatinib overlaps with the LIF and occupies the active site. LIF established different interactions with human VEGFR2, including 6 van der Waals (vdW) contacts (leu35, Val43, Glu112, Lys115, Gly117, Asn118) and 5 hydrophobic interactions (Leu35, Val43, Ala61, Gly117, Leu180) (<xref rid="pone.0330841.g007" ref-type="fig">Fig 7B</xref>). Likewise, ponatinib formed many interactions with human VEGFR2 including 10 vdW contacts (Leu35, Cys114, Lys115, Gly117, Asn118, Arg177, Leu180, Phe192, Arg196, Asp197) and 6 hydrophobic interactions (Val43, Asn118, Arg177, Phe192, Arg196, Asp197) (<xref rid="pone.0330841.g007" ref-type="fig">Fig 7C</xref>).</p><fig position="float" id="pone.0330841.g007" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g007</object-id><label>Fig 7</label><caption><title>The binding conformation of LIF and ponatinib within the binding pocket of human VEGFR2.</title><p><bold>(A)</bold> 3D interactions of LIF (red) and ponatinib (blue) with human VEGFR2 (tan). <bold>(B)</bold> Interactions map of LIF with human VEGFR2. <bold>(C)</bold> Interactions map of ponatinib with human VEGFR2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g007.jpg"/></fig></sec><sec id="sec024"><title>Molecular dynamics simulation</title><p>The RMSD is an fundamental parameter employed to evaluate structural deviations and the overall stability of proteins [<xref rid="pone.0330841.ref062" ref-type="bibr">62</xref>]. The RMSD plot of free VEGFR2 increased from 1.1 &#197; to 3.9 &#197; during the first 60 ns of the simulation, then fluctuated between 2.5 &#197; and 3.5 &#197; until the end. The RMSD plot of the VEGFR2-LIF complex indicates a minimum value of 0.9 &#197; and a maximum value of 2.9 &#197;, whereas the RMSD plot for the VEGFR2-ponatinib complex reveals a minimum value of 0 &#197; and a maximum value of 2.9 &#197; (<xref rid="pone.0330841.g008" ref-type="fig">Fig 8A</xref>). The fluctuations of residues during the simulation were evaluated using an RMSF analysis. The RMSF plot for the initial 75 residues of the free VEGFR2 exhibited greater fluctuations compared to the VEGFR2 complexed with LIF and ponatinib. Beyond this segment, with the exception of minor fluctuations, the RMSF plots s for VEGFR2, VEGFR2-LIF, and VEGFR2-ponatinib complexes overlapped throughout the simulation (<xref rid="pone.0330841.g008" ref-type="fig">Fig 8B</xref>). Rg denotes the folding rate and quantifies the protein&#8217;s compactness during simulation [<xref rid="pone.0330841.ref063" ref-type="bibr">63</xref>]; typically, a protein with a greater Rg indicates a less densely packed structure [<xref rid="pone.0330841.ref064" ref-type="bibr">64</xref>]. The maximal Rg values for VEGFR2, VEGFR2-LIF, and VEGFR2-ponatinib complexes were 21.05 &#197;, 21.2 &#197;, and 21.25 &#197;, respectively (<xref rid="pone.0330841.g008" ref-type="fig">Fig 8C</xref>). SASA is a measurement of a protein structure&#8217;s surface area that solvent molecules can access [<xref rid="pone.0330841.ref065" ref-type="bibr">65</xref>]. The SASA plots for VEGFR2, VEGFR2-LIF, and VEGFR2-ponatinib were nearly overlapping during the initial 23 ns. Within the range of 23&#8211;50 ns, the least SASA value was seen for VEGFR2, whereas the maximum SASA value was recorded for VEGFR2-ponatinib. During the final 20 ns of the simulation, the VEGFR2 plot fluctuated, whereas the VEGFR2-LIF and VEGFR2- ponatinib plots reached almost steady state (<xref rid="pone.0330841.g008" ref-type="fig">Fig 8D</xref>).</p><fig position="float" id="pone.0330841.g008" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.g008</object-id><label>Fig 8</label><caption><title>A graphical representation of the MD simulation results.</title><p><bold>(A)</bold> RMSD plot. <bold>(B)</bold> RMSF plot. <bold>(C)</bold> Rg plot. <bold>(D)</bold> SASA plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0330841.g008.jpg"/></fig></sec><sec id="sec025"><title>MM-PBSA/GBSA analysis</title><p>The MM-GBSA and MM-PBSA methods were used to calculate the binding free energies of VEGFR2-LIF and VEGFR2-ponatinib complexes. The total MM-GBSA binding free energy was &#8722;82.51&#8201;&#177;&#8201;5.20 kcal/mol and &#8722;85.52&#8201;&#177;&#8201;5.06 for VEGFR2-LIF and VEGFR2-ponatinib complexes, respectively. The total MM-PBSA binding free energy was &#8722;82.38&#8201;&#177;&#8201;5.34 kcal/mol and &#8722;84.89&#8201;&#177;&#8201;5.65 kcal/mol for VEGFR2-LIF and VEGFR2-ponatinib complexes, respectively. The computed values indicate that the contributions of vdW energy are substantial in both methods. The contributions of each energy component are presented in <xref rid="pone.0330841.t003" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="pone.0330841.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0330841.t003</object-id><label>Table 3</label><caption><title>Binding free energy value for VEGFR2-LIF and VEGFR2-ponatinib complexes.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0330841.t003g" position="float" orientation="portrait" xlink:href="pone.0330841.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Method</th><th align="left" rowspan="1" colspan="1">Energy section</th><th align="left" rowspan="1" colspan="1">VEGFR2-LIF complex (kcal/mol) &#177; Standard Deviation</th><th align="left" rowspan="1" colspan="1">VEGFR2-ponatinib complex (kcal/mol) &#177; Standard Deviation</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">
<bold>MM-GBSA</bold>
</td><td align="left" rowspan="1" colspan="1">van der Waals energy</td><td align="left" rowspan="1" colspan="1">&#8722;75.69&#8201;&#177;&#8201;5.36</td><td align="left" rowspan="1" colspan="1">&#8722;78.52&#8201;&#177;&#8201;5.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Electrostatic energy</td><td align="left" rowspan="1" colspan="1">&#8722;24.36&#8201;&#177;&#8201;3.57</td><td align="left" rowspan="1" colspan="1">&#8722;25.87&#8201;&#177;&#8201;2.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Solvation energy (SE)</td><td align="left" rowspan="1" colspan="1">17.54&#8201;&#177;&#8201;2.56</td><td align="left" rowspan="1" colspan="1">18.87&#8201;&#177;&#8201;2.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Gas phase energy</td><td align="left" rowspan="1" colspan="1">&#8722;100.05&#8201;&#177;&#8201;4.85</td><td align="left" rowspan="1" colspan="1">&#8722;104.39&#8201;&#177;&#8201;6.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Total binding energy</td><td align="left" rowspan="1" colspan="1">&#8722;82.51&#8201;&#177;&#8201;5.20</td><td align="left" rowspan="1" colspan="1">&#8722;85.52&#8201;&#177;&#8201;5.06</td></tr><tr><td align="left" rowspan="5" colspan="1">
<bold>MM-PBSA</bold>
</td><td align="left" rowspan="1" colspan="1">van der Waals energy</td><td align="left" rowspan="1" colspan="1">&#8722;75.69&#8201;&#177;&#8201;5.36</td><td align="left" rowspan="1" colspan="1">&#8722;78.52&#8201;&#177;&#8201;5.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Electrostatic energy</td><td align="left" rowspan="1" colspan="1">&#8722;24.36&#8201;&#177;&#8201;3.57</td><td align="left" rowspan="1" colspan="1">&#8722;25.87&#8201;&#177;&#8201;2.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Salvation energy (SE)</td><td align="left" rowspan="1" colspan="1">17.67&#8201;&#177;&#8201;2.59</td><td align="left" rowspan="1" colspan="1">19.50&#8201;&#177;&#8201;2.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Gas phase energy</td><td align="left" rowspan="1" colspan="1">&#8722;100.05&#8201;&#177;&#8201;4.85</td><td align="left" rowspan="1" colspan="1">&#8722;104.39&#8201;&#177;&#8201;6.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Total binding energy</td><td align="left" rowspan="1" colspan="1">&#8722;82.38&#8201;&#177;&#8201;5.34</td><td align="left" rowspan="1" colspan="1">&#8722;84.89&#8201;&#177;&#8201;5.65</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec026"><title>Discussion</title><p>Endometriosis, a chronic and often painful systemic disorder, can negatively impact physical and mental health, quality of life, and productivity. This condition imposes substantial economic and social burdens on patients, their families, and society at large. Despite its prevalence and considerable costs, endometriosis receives minimal funding and research attention, significantly limiting our understanding of the disorder; therefore, urgent investigation into its diagnosis and treatment is necessary [<xref rid="pone.0330841.ref066" ref-type="bibr">66</xref>].</p><p>Bioinformatics analysis can find diagnostic markers, providing potential biomarkers for human disease diagnosis and improving our understanding of disease pathophysiology [<xref rid="pone.0330841.ref067" ref-type="bibr">67</xref>]. In this study, to identify effective diagnostic biomarkers for endometriosis patients, the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset, which contains gene expression data of fertile and infertile women with endometriosis and their control groups, was downloaded from the GEO database and integrated analysis was performed. In this work, 708 common up-regulated DEGs and 414 common down-regulated DEGs were found between FE and IE.</p><p>GO enrichment analysis indicated that the most of the common up-regulated DEGs between FE and IE were mainly associated with four GO BP terms (i.e., regulation of response to stimulus, system development, cellular developmental process, and cell differentiation), six GO MF terms (i.e., cation binding, metal ion binding, nucleic acid binding, DNA binding, transcription regulator activity, and double-stranded DNA binding), and three GO CC terms (i.e., cell projection, plasma membrane bounded cell projection, and neuron projection).</p><p>The highest number of the common up-regulated DEGs between FE and IE were associated with four KEGG pathways including herpes simplex virus (HSV) 1 infection, mitogen-activated protein kinase (MAPK) signaling pathway, phosphatidylinositol 3-kinase-protein kinase B (PI3K/AKT) signaling pathway, and cytoskeleton in muscle cells. Cong <italic toggle="yes">et al</italic>. reported in their study that the herpes simplex virus (HSV) 1 infection pathway is implicated in endometriosis [<xref rid="pone.0330841.ref068" ref-type="bibr">68</xref>]. HSV is the primary agent responsible for infections in the oro-facial regions and genital tracts. Farsimadan <italic toggle="yes">et al</italic>. claimed that HSV is associated with infertility [<xref rid="pone.0330841.ref069" ref-type="bibr">69</xref>]. Consequently, HSV may cause female infertility by damaging the endometrium. Honda <italic toggle="yes">et al</italic>. demonstrated that both MAPK and PI3K/AKT pathways are constitutively active in ovarian endometriosis [<xref rid="pone.0330841.ref070" ref-type="bibr">70</xref>]. The MAPK pathway promotes the development and maintenance of ectopic endometrial tissues by influencing the actions of several cytokines, whereas the PI3K/AKT pathway enhances cell survival, proliferation, and migration [<xref rid="pone.0330841.ref071" ref-type="bibr">71</xref>]. To confirm the correlation of these pathways with endometriosis, the expression of each protein within these pathways can be evaluated in vitro in endometriosis by immunohistochemistry (IHC) and Western blot analysis. The expression levels of the genes that encode these proteins can be evaluated using real-time polymerase chain reaction (PCR). Cao et <italic toggle="yes">al</italic>. evaluated the dose-dependent inhibitory effect of ginsenoside Rg3 on ectopic endometrial development in treated mice vs the control group. Immunohistochemistry and Western blotting validated that the expression levels of VEGF, p-Akt, and p-mTOR were down-regulated in lesions subjected to ginsenoside Rg3 treatment. Real-time PCR results indicated that the mRNA expression levels of VEGF, Akt, and mTOR were decreased in ectopic endometrium [<xref rid="pone.0330841.ref072" ref-type="bibr">72</xref>].</p><p>Based on the PPI network of shared up-regulated DEGs in the FE and IE groups, we identified two potential hub genes: VEGFR2 and IL-6. VEGFs and their receptors (VEGFRs) are the most critical and particular factors that promote the proliferation of endothelial cells, regulate the development of blood vessels from precursor cells during early embryogenesis and the formation of blood vessels from preexisting vessels later on, and improve vascular endothelial cells&#8217; chemotaxis and vascular permeability [<xref rid="pone.0330841.ref073" ref-type="bibr">73</xref>,<xref rid="pone.0330841.ref074" ref-type="bibr">74</xref>]. VEGFR2 is activated upon VEGF binding, initiating a phosphorylation process that enhances endothelial cell proliferation and migration [<xref rid="pone.0330841.ref075" ref-type="bibr">75</xref>,<xref rid="pone.0330841.ref076" ref-type="bibr">76</xref>]. The study by Cao et al. suggests that VEGF binding to VEGFR2 in vascular endothelial cells increases vascular permeability, enhances ectopic endometrial cell invasion and angiogenesis, promotes cell proliferation, and reduces cell apoptosis, ultimately leading to endometriosis [<xref rid="pone.0330841.ref072" ref-type="bibr">72</xref>]. VEGFA signaling via VEGFR2 is well known to promote angiogenesis and facilitate the growth of endometrial lesions [<xref rid="pone.0330841.ref077" ref-type="bibr">77</xref>&#8211;<xref rid="pone.0330841.ref079" ref-type="bibr">79</xref>]. Studies have indicated that VEGFR2 is significantly elevated in endometriotic tissues [<xref rid="pone.0330841.ref077" ref-type="bibr">77</xref>,<xref rid="pone.0330841.ref080" ref-type="bibr">80</xref>]. Bourlev <italic toggle="yes">et al</italic>. reported elevated expression of VEGFR2 in the blood vessels of eutopic endometrium from women with endometriosis compared to those without the condition [<xref rid="pone.0330841.ref081" ref-type="bibr">81</xref>].</p><p>IL-6 is a pro-inflammatory cytokine that is mostly produced by monocytes and macrophages, although it can also be secreted by T lymphocytes, B lymphocytes, hepatocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells, and other tumor cells [<xref rid="pone.0330841.ref082" ref-type="bibr">82</xref>]. Incognito <italic toggle="yes">et al</italic>. conducted a systematic review that included all studies published up to December 2022 that assessed IL-6 in serum, peritoneal fluid, follicular fluid, or endometrial biopsy samples, correlating their findings with endometriosis-related infertility. This study&#8217;s results indicated a correlation between elevated blood and peritoneal fluid IL-6 levels and the incidence of endometriosis-related infertility [<xref rid="pone.0330841.ref083" ref-type="bibr">83</xref>]. Increased concentrations of IL-6 in the peritoneal fluid of patients with endometriosis underscore its role in disease progression. According to studies, IL-6 activates macrophages, which can enhance endometrial cell proliferation [<xref rid="pone.0330841.ref084" ref-type="bibr">84</xref>]. Research demonstrates that IL-6, in conjunction with other cytokines, cultivates a peritoneal milieu favorable for the implantation and proliferation of endometriotic cells, underscoring its importance in endometriosis and various inflammatory and autoimmune disorders [<xref rid="pone.0330841.ref085" ref-type="bibr">85</xref>].</p><p>miRNAs are diminutive non-coding RNAs, averaging 22 nucleotides in length. The majority of miRNAs are transcribed from DNA sequences into primary miRNAs (pri-miRNAs), which are further processed into precursor miRNAs (pre-miRNAs) and mature miRNAs. In the majority of instances, miRNAs engage with the 3&#8242; UTR of target mRNAs to inhibit expression [<xref rid="pone.0330841.ref086" ref-type="bibr">86</xref>]. miRNAs have been identified as possible biomarkers for the diagnosis of endometriosis. Several miRNAs associated with this condition have been published, including miR-451, the miR-200 family, miR-199, and miR-125 [<xref rid="pone.0330841.ref087" ref-type="bibr">87</xref>]. In this study, we predicted that three miRNA targets, hsa-miR-155-5p, hsa-miR-335-5p, and hsa-miR-199a-3p, regulate both hub genes. Daikoku <italic toggle="yes">et al</italic>. reported down-regulated expression of miR-199a-3p in the endometrium, which was associated with up-regulated expression of the cyclooxygenase-2 (Cox-2) gene, implying that low expression levels of miR199a-3p may correlate with the development of endometrial cancer [<xref rid="pone.0330841.ref088" ref-type="bibr">88</xref>].</p><p>Furthermore, both hub genes were associated with the TF targets FOXC1 and STAT3. FOXC1 is a major member of the FOX protein family, exhibiting abnormal expression in endometrial cancer and potentially influencing the migration and invasion of this malignancy; however, its mechanism of action is unknown [<xref rid="pone.0330841.ref089" ref-type="bibr">89</xref>]. In endometrial cancer, the downregulation of FOXC1 by miRNA, specifically miRNA 204 and miRNA 495, inhibits cancer cell proliferation and migration [<xref rid="pone.0330841.ref090" ref-type="bibr">90</xref>,<xref rid="pone.0330841.ref091" ref-type="bibr">91</xref>], suggesting that FOXC1 may possibly act as a potential oncogene in endometrial carcinoma [<xref rid="pone.0330841.ref092" ref-type="bibr">92</xref>]. FOXC1 stimulates VEGF expression via Notch signaling pathways [<xref rid="pone.0330841.ref093" ref-type="bibr">93</xref>]; the association of increased VEGF expression with endometrial cancer angiogenesis shows that FOXC1 is an important angiogenic and prognostic factor [<xref rid="pone.0330841.ref094" ref-type="bibr">94</xref>]. Chen <italic toggle="yes">et al</italic>. revealed that STAT3 is active in human endometrial and cervical cancers, and that inhibiting constitutive STAT3 signaling may serve as an effective target for intervention in these malignancies [<xref rid="pone.0330841.ref095" ref-type="bibr">95</xref>]. Kim <italic toggle="yes">et al</italic>. indicated that phosphorylated STAT3 is significantly expressed and activated in the endometrium of individuals with endometriosis [<xref rid="pone.0330841.ref096" ref-type="bibr">96</xref>].</p><p>We employed DGIdb 5.0 to identify potentially druggable genes among hub genes and TFs predicted to interact with drugs. Evaluation indicated that VEGFR2 may be a superior candidate for druggability compared to other hub gene and TFs. 16 FDA-approved drugs, along with the co-crystal ligand (LIF), were docked against VEGFR2. The docked complexes were assessed according to binding energy. Among 16 FDA-approved drugs, ponatinib had a greater negative energy than LIF. ProLIF analysis revealed that LIF is well packed into the VEGFR2 binding site. Binding affinity may be moderate and specificity may be lower due to the non-specific nature of vdW interactions. It was also shown that ponatinib not only fits tightly into the binding site, but also forms several strong interactions and binding specificity, resulting in higher affinity and better binding specificity than LIF. This analysis confirms that ponatinib binds more tightly to VEGFR2 than LIF based on the richness of interactions, diversity, and interaction of both non-polar and polar residues. The insights derived from this thorough interaction study illuminate potential mechanisms by which ponatinib may influence VEGFR2 function. This enhances its potential as a promising candidate for the treatment of endometriosis. Ponatinib, a powerful tyrosine kinase inhibitor (TKI), was initially developed to target the BCR-ABL1 oncoprotein. Several studies have shown that ponatinib blocks a wide range of additional oncogenic tyrosine kinases upstream of MAPK and PI3K [<xref rid="pone.0330841.ref097" ref-type="bibr">97</xref>,<xref rid="pone.0330841.ref098" ref-type="bibr">98</xref>]. MAPK signaling kinases are classified into three families: extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) [<xref rid="pone.0330841.ref099" ref-type="bibr">99</xref>]. The study conducted by Ng&#244; <italic toggle="yes">et al</italic>. demonstrates that endometriotic cells, in conjunction with endometrial cells from patients with endometriosis, activated the ERK pathway more significantly than endometrial cells from healthy individuals. This occurrence was associated with a heightened proliferation of endometriotic cells compared to endometrial cells. [<xref rid="pone.0330841.ref100" ref-type="bibr">100</xref>]. The activation of the PI3K/AKT/mTOR signaling pathway is significant throughout the transformation from normal endometrium to endometriosis, as revealed by the changed expression of essential pathway components in both eutopic and ectopic endometrium [<xref rid="pone.0330841.ref101" ref-type="bibr">101</xref>].</p><p>An RMSD value of &lt;3&#197; is acceptable. The higher the RMSD value, the more deviation from the protein&#8217;s original conformation occurs [<xref rid="pone.0330841.ref102" ref-type="bibr">102</xref>]. The RMSD plot demonstrates that in the last 50 ns of the simulation, the RMSD of the VEGFR2 is larger than 3 &#197;, while the RMSD of the VEGFR2-LIF and VEGFR2-ponatinib complexes is less than 3 &#197;. The fluctuations in the VEGFR2-ponatinib complex are lower than in the VEGFR2-LIF complex. This observation could be ascribed to ponatinib&#8217;s numerous interactions with the active binding region of VEGFR2, which resulted in fewer conformational changes and a relatively stable pose. The RMSF plots of the VEGFR2-LIF and VEGFR2-ponatinib complexes exhibit lower residue fluctuations and lower RMSF values compared to the VEGFR2 residues. The results indicate that LIF and ponatinib can establish appropriate and stable interactions with the active site of VEGFR2 during the simulation. These results align with the findings from the RMSD results. The Rg plot revealed a lower value for free VEGFR2 compared to both VEGFR2-LIF and VEGFR2-ponatinib complexes, indicating a more compact VEGFR2 structure in the free state. The SASA plot indicated that the SASA values for both VEGFR2-LIF and VEGFR2-ponatinib complexes were close to those of free VEGFR2 for the majority of the simulation duration. Ponatinib exhibits a stronger binding affinity to VEGFR2 compared to LIF, as indicated by lower total binding energies in both MM-GBSA and MM-PBSA analyses. The energy contributions, especially from vdW and electrostatic interactions, support a more favorable and stable interaction profile for ponatinib.</p><p>This study enhances our comprehension of the molecular pathophysiology of endometriosis and subsequently offers new avenues for detection and targeting to improve therapy strategies. This computational work has identified a potential biomarker and an associated candidate drug through the analysis of extensive biological data; nonetheless, it is important to recognize the limits of this study. The sample size in our study is constrained, and we did not account for individual variations. A more reliable outcome could be attained by integrating additional data sets and samples in a subsequent experiment. This computational analysis cannot directly prescribe treatment for the condition. To authenticate our computational findings and further evaluate the therapeutic potential of the identified biomarker and corresponding candidate drug, we recommend for experimental validation via cellular assays and the establishment of animal models to assess their efficacy and safety in a more biologically pertinent context.</p></sec><sec sec-type="conclusions" id="sec027"><title>Conclusion</title><p>The computational findings of this study suggest that VEGFR2 is a promising target for endometriosis treatment. This study assessed FDA-approved drugs for their ability to target the VEGFR2 protein in diseased situations. The virtual screening approach commenced with molecular docking of 16 FDA-approved pharmaceuticals, followed by an evaluation of binding affinity. Ponatinib exhibited superior binding affinity compared to the ligand within the structure. Moreover, interaction analysis demonstrated that both occupy the identical binding pocket and interact with essential amino acids. MD simulations lasting 100 ns were used to analyze the docked complexes. MD simulations validated the structural stability of the ponatinib-VEGFR2 complex. Based on these findings, ponatinib has been discovered as a viable endometriosis treatment. However, more experimental and clinical trials studies are needed to corroborate these findings and investigate the therapeutic potential of ponatinib for endometriosis.</p></sec><sec id="sec028" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0330841.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Table</label><caption><title>The up- and down-regulated DEGs between groups in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE120103">GSE120103</ext-link> dataset.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s002" position="float" content-type="local-data" orientation="portrait"><label>S2 Table</label><caption><title>The list of functional analysis of enriched GO BP terms of common up-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s003" position="float" content-type="local-data" orientation="portrait"><label>S3 Table</label><caption><title>The list of functional analysis of enriched GO MF terms of common up-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s003.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s004" position="float" content-type="local-data" orientation="portrait"><label>S4 Table</label><caption><title>The list of functional analysis of enriched GO CC terms of common up-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s004.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s005" position="float" content-type="local-data" orientation="portrait"><label>S5 Table</label><caption><title>The list of functional analysis of enriched GO BP terms of common down-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s005.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s006" position="float" content-type="local-data" orientation="portrait"><label>S6 Table</label><caption><title>The list of functional analysis of enriched GO MF terms of common down-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s006.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s007" position="float" content-type="local-data" orientation="portrait"><label>S7 Table</label><caption><title>The list of functional analysis of enriched GO CC terms of common down-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s007.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s008" position="float" content-type="local-data" orientation="portrait"><label>S8 Table</label><caption><title>The list of KEGG pathways involving common up-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s008.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s009" position="float" content-type="local-data" orientation="portrait"><label>S9 Table</label><caption><title>The list of KEGG pathways involving common down-regulated DEGs between the FE and IE groups.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s009.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s010" position="float" content-type="local-data" orientation="portrait"><label>S10 Table</label><caption><title>The top 10 ranked hub genes by the Betweenness, BottleNeck, Closeness, Degree, and Stress algorithms in the CytoHubba plugin of Cytoscape.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s010.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s011" position="float" content-type="local-data" orientation="portrait"><label>S11 Table</label><caption><title>The list of nodes inside the miRNAs/TFs-IL-6 network.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s011.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s012" position="float" content-type="local-data" orientation="portrait"><label>S12 Table</label><caption><title>The list of nodes inside the miRNAs/TFs-KDR network.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s012.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s013" position="float" content-type="local-data" orientation="portrait"><label>S1 File</label><caption><title>This file is PDB format structure of the human VEGFR2 protein (ID: 1YWN) in complex with leukaemia inhibitory factor (LIF).</title><p>(PDB).</p><p>(PDB)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s013.pdb" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s014" position="float" content-type="local-data" orientation="portrait"><label>S2 File</label><caption><title>This file is prepared structure of the human VEGFR2 protein.</title><p>(PDB).</p><p>(PDB)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s014.pdb" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0330841.s015" position="float" content-type="local-data" orientation="portrait"><label>S3 File</label><caption><title>This file contains of 16 FDA-approved drugs in SDF format was obtained from the DrugBank database.</title><p>(ZIP)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0330841.s015.rar" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank the Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences, Semnan, Iran</p></ack><ref-list><title>References</title><ref id="pone.0330841.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization (WHO). Endometriosis. [cited March 24, 2023]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/endometriosis" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/endometriosis</ext-link></mixed-citation></ref><ref id="pone.0330841.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name>. <article-title>A novel and compact review on the role of oxidative stress in female reproduction</article-title>. <source>Reprod Biol Endocrinol</source>. <year>2018</year>;<volume>16</volume>(<issue>1</issue>):<fpage>80</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12958-018-0391-5</pub-id><pub-id pub-id-type="pmid">30126412</pub-id><pub-id pub-id-type="pmcid">PMC6102891</pub-id></mixed-citation></ref><ref id="pone.0330841.ref003"><label>3</label><mixed-citation publication-type="book"><name name-style="western"><surname>Farland</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Kvaskoff</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zondervan</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Missmer</surname><given-names>SA.</given-names></name><article-title>Epidemiological and clinical risk factors for endometriosis.</article-title> In: <name name-style="western"><surname>D&#8217;Hooghe</surname><given-names>T</given-names></name>, editor. <source>Biomarkers for endometriosis: state of the art</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>. <year>2017</year>. p. <fpage>95</fpage>&#8211;<lpage>121</lpage>.</mixed-citation></ref><ref id="pone.0330841.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tokushige</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Markham</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>IS</given-names></name>. <article-title>Rich innervation of deep infiltrating endometriosis</article-title>. <source>Hum Reprod</source>. <year>2009</year>;<volume>24</volume>(<issue>4</issue>):<fpage>827</fpage>&#8211;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/humrep/den464</pub-id><pub-id pub-id-type="pmid">19151028</pub-id></mixed-citation></ref><ref id="pone.0330841.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Taylor</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Kotlyar</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Flores</surname><given-names>VA</given-names></name>. <article-title>Endometriosis is a chronic systemic disease: clinical challenges and novel innovations</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10276</issue>):<fpage>839</fpage>&#8211;<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00389-5</pub-id><pub-id pub-id-type="pmid">33640070</pub-id></mixed-citation></ref><ref id="pone.0330841.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eskenazi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Warner</surname><given-names>ML</given-names></name>. <article-title>Epidemiology of endometriosis</article-title>. <source>Obstet Gynecol Clin North Am</source>. <year>1997</year>;<volume>24</volume>(<issue>2</issue>):<fpage>235</fpage>&#8211;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0889-8545(05)70302-8</pub-id><pub-id pub-id-type="pmid">9163765</pub-id></mixed-citation></ref><ref id="pone.0330841.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rocha</surname><given-names>ALL</given-names></name>, <name name-style="western"><surname>Reis</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>RN</given-names></name>. <article-title>Angiogenesis and endometriosis</article-title>. <source>Obstet Gynecol Int</source>. <year>2013</year>;<volume>2013</volume>:<fpage>859619</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2013/859619</pub-id><pub-id pub-id-type="pmid">23766765</pub-id><pub-id pub-id-type="pmcid">PMC3677669</pub-id></mixed-citation></ref><ref id="pone.0330841.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hadfield</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mardon</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Barlow</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>S</given-names></name>. <article-title>Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK</article-title>. <source>Hum Reprod</source>. <year>1996</year>;<volume>11</volume>(<issue>4</issue>):<fpage>878</fpage>&#8211;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/oxfordjournals.humrep.a019270</pub-id><pub-id pub-id-type="pmid">8671344</pub-id></mixed-citation></ref><ref id="pone.0330841.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>D&#8217;Hooghe</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Debrock</surname><given-names>S</given-names></name>. <article-title>Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons</article-title>. <source>Hum Reprod Update</source>. <year>2002</year>;<volume>8</volume>(<issue>1</issue>):<fpage>84</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/humupd/8.1.84</pub-id><pub-id pub-id-type="pmid">11866244</pub-id></mixed-citation></ref><ref id="pone.0330841.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bazot</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bharwani</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Huchon</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kinkel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cunha</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Guerra</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis</article-title>. <source>Eur Radiol</source>. <year>2017</year>;<volume>27</volume>(<issue>7</issue>):<fpage>2765</fpage>&#8211;<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00330-016-4673-z</pub-id><pub-id pub-id-type="pmid">27921160</pub-id><pub-id pub-id-type="pmcid">PMC5486785</pub-id></mixed-citation></ref><ref id="pone.0330841.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Guerriero</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Condous</surname><given-names>G</given-names></name>, <name name-style="western"><surname>van den Bosch</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Valentin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Leone</surname><given-names>FPG</given-names></name>, <name name-style="western"><surname>Van Schoubroeck</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group</article-title>. <source>Ultrasound Obstet Gynecol</source>. <year>2016</year>;<volume>48</volume>(<issue>3</issue>):<fpage>318</fpage>&#8211;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/uog.15955</pub-id><pub-id pub-id-type="pmid">27349699</pub-id></mixed-citation></ref><ref id="pone.0330841.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Keckstein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoopmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Merz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Grab</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Weichert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Helmy-Bader</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Expert opinion on the use of transvaginal sonography for presurgical staging and classification of endometriosis</article-title>. <source>Arch Gynecol Obstet</source>. <year>2023</year>;<volume>307</volume>(<issue>1</issue>):<fpage>5</fpage>&#8211;<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00404-022-06766-z</pub-id><pub-id pub-id-type="pmid">36367580</pub-id><pub-id pub-id-type="pmcid">PMC9837004</pub-id></mixed-citation></ref><ref id="pone.0330841.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sahoo</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Ravi Kumar</surname><given-names>BVV</given-names></name>, <name name-style="western"><surname>Sruti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mahapatra</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Banik</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Borah</surname><given-names>P</given-names></name>. <article-title>Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection</article-title>. <source>Front Mol Biosci</source>. <year>2021</year>;<volume>8</volume>:<fpage>628144</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmolb.2021.628144</pub-id><pub-id pub-id-type="pmid">33718434</pub-id><pub-id pub-id-type="pmcid">PMC7953054</pub-id></mixed-citation></ref><ref id="pone.0330841.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cha</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Erez</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>IJ</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koytiger</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Drug repurposing from the perspective of pharmaceutical companies</article-title>. <source>Br J Pharmacol</source>. <year>2018</year>;<volume>175</volume>(<issue>2</issue>):<fpage>168</fpage>&#8211;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bph.13798</pub-id><pub-id pub-id-type="pmid">28369768</pub-id><pub-id pub-id-type="pmcid">PMC5758385</pub-id></mixed-citation></ref><ref id="pone.0330841.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Usmani Rana</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Nisar</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Prajapati</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Goswami</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rawat</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Eyupoglu</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Integrative bioinformatic analysis to identify potential phytochemical candidates for glioblastoma</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>24</issue>):e40744. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e40744</pub-id><pub-id pub-id-type="pmid">39720087</pub-id><pub-id pub-id-type="pmcid">PMC11665539</pub-id></mixed-citation></ref><ref id="pone.0330841.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Islam</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gov</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Turanli</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gulfidan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Haque</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses</article-title>. <source>OMICS</source>. <year>2018</year>;<volume>22</volume>(<issue>6</issue>):<fpage>422</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1089/omi.2018.0048</pub-id><pub-id pub-id-type="pmid">29927717</pub-id></mixed-citation></ref><ref id="pone.0330841.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rahman</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Turanli</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zaman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Faruquee</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer&#8217;s disease</article-title>. <source>Comput Biol Chem</source>. <year>2019</year>;<volume>78</volume>:<fpage>431</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2018.12.011</pub-id><pub-id pub-id-type="pmid">30606694</pub-id></mixed-citation></ref><ref id="pone.0330841.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Santiago</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Bottero</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Potashkin</surname><given-names>JA</given-names></name>. <article-title>Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology</article-title>. <source>Front Aging Neurosci</source>. <year>2017</year>;<volume>9</volume>:<fpage>166</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnagi.2017.00166</pub-id><pub-id pub-id-type="pmid">28611656</pub-id><pub-id pub-id-type="pmcid">PMC5446999</pub-id></mixed-citation></ref><ref id="pone.0330841.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vercellini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Donati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ottolini</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Frassineti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fiorini</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nebuloni</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>A stepped-care approach to symptomatic endometriosis management: a participatory research initiative</article-title>. <source>Fertil Steril</source>. <year>2018</year>;<volume>109</volume>(<issue>6</issue>):<fpage>1086</fpage>&#8211;<lpage>96</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.fertnstert.2018.01.037</pub-id><pub-id pub-id-type="pmid">29871796</pub-id></mixed-citation></ref><ref id="pone.0330841.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dunselman</surname><given-names>GAJ</given-names></name>, <name name-style="western"><surname>Vermeulen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Calhaz-Jorge</surname><given-names>C</given-names></name>, <name name-style="western"><surname>D&#8217;Hooghe</surname><given-names>T</given-names></name>, <name name-style="western"><surname>De Bie</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>ESHRE guideline: management of women with endometriosis</article-title>. <source>Hum Reprod</source>. <year>2014</year>;<volume>29</volume>(<issue>3</issue>):<fpage>400</fpage>&#8211;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/humrep/det457</pub-id><pub-id pub-id-type="pmid">24435778</pub-id></mixed-citation></ref><ref id="pone.0330841.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gou</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Tanshinone &#8545;A participates in the treatment of endometriosis by regulating adhesion, invasion, angiogenesis and inhibition of PI3K/Akt/mTOR signaling pathway</article-title>. <source>Mol Med Rep</source>. <year>2023</year>;<volume>28</volume>(<issue>5</issue>):<fpage>221</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/mmr.2023.13108</pub-id><pub-id pub-id-type="pmid">37800602</pub-id><pub-id pub-id-type="pmcid">PMC10568248</pub-id></mixed-citation></ref><ref id="pone.0330841.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Edgar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Domrachev</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lash</surname><given-names>AE</given-names></name>. <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>. <year>2002</year>;<volume>30</volume>(<issue>1</issue>):<fpage>207</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/30.1.207</pub-id><pub-id pub-id-type="pmid">11752295</pub-id><pub-id pub-id-type="pmcid">PMC99122</pub-id></mixed-citation></ref><ref id="pone.0330841.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bhat</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Sengupta</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>D</given-names></name>. <article-title>Genomic evidence of Y chromosome microchimerism in the endometrium during endometriosis and in cases of infertility</article-title>. <source>Reprod Biol Endocrinol</source>. <year>2019</year>;<volume>17</volume>(<issue>1</issue>):<fpage>22</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12958-019-0465-z</pub-id><pub-id pub-id-type="pmid">30760267</pub-id><pub-id pub-id-type="pmcid">PMC6375207</pub-id></mixed-citation></ref><ref id="pone.0330841.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ritchie</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Phipson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>(<issue>7</issue>):e47. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="pmcid">PMC4402510</pub-id></mixed-citation></ref><ref id="pone.0330841.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Allaire</surname><given-names>J</given-names></name>. <article-title>RStudio: integrated development environment for R</article-title>. <source>Journal Title Abbreviation</source>. <year>2012</year>;<volume>770</volume>(<issue>394</issue>):<fpage>165</fpage>&#8211;<lpage>71</lpage>.</mixed-citation></ref><ref id="pone.0330841.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Villanueva</surname><given-names>RAM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>ZJ</given-names></name>. <article-title>ggplot2: Elegant Graphics for Data Analysis (2nd ed.)</article-title>. <source>Measurement: Interdisciplinary Research and Perspectives</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>160</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/15366367.2019.1565254</pub-id></mixed-citation></ref><ref id="pone.0330841.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Boutros</surname><given-names>PC</given-names></name>. <article-title>VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R</article-title>. <source>BMC Bioinformatics</source>. <year>2011</year>;<volume>12</volume>:<fpage>35</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2105-12-35</pub-id><pub-id pub-id-type="pmid">21269502</pub-id><pub-id pub-id-type="pmcid">PMC3041657</pub-id></mixed-citation></ref><ref id="pone.0330841.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ge</surname><given-names>SX</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>R</given-names></name>. <article-title>ShinyGO: a graphical gene-set enrichment tool for animals and plants</article-title>. <source>Bioinformatics</source>. <year>2020</year>;<volume>36</volume>(<issue>8</issue>):<fpage>2628</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btz931</pub-id><pub-id pub-id-type="pmid">31882993</pub-id><pub-id pub-id-type="pmcid">PMC7178415</pub-id></mixed-citation></ref><ref id="pone.0330841.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sherman</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Baseler</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>HC</given-names></name>, <etal>et al</etal>. <article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update</article-title><source>). Nucleic Acids Research</source>. <year>2022</year>;<volume>50</volume>(W1):W216&#8211;<lpage>W21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmcid">PMC9252805</pub-id><pub-id pub-id-type="pmid">35325185</pub-id></mixed-citation></ref><ref id="pone.0330841.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kirsch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Koutrouli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nastou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mehryary</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hachilif</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title>. <source>Nucleic Acids Res</source>. <year>2023</year>;<volume>51</volume>(D1):D638&#8211;<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="pmcid">PMC9825434</pub-id></mixed-citation></ref><ref id="pone.0330841.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shannon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Markiel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ozier</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Baliga</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Ramage</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res</source>. <year>2003</year>;<volume>13</volume>(<issue>11</issue>):<fpage>2498</fpage>&#8211;<lpage>504</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id><pub-id pub-id-type="pmcid">PMC403769</pub-id></mixed-citation></ref><ref id="pone.0330841.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chin</surname><given-names>C-H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S-H</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H-H</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>C-W</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>M-T</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C-Y</given-names></name>. <article-title>cytoHubba: identifying hub objects and sub-networks from complex interactome</article-title>. <source>BMC Syst Biol</source>. <year>2014</year>;<volume>8</volume>(Suppl 4):S11. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1752-0509-8-S4-S11</pub-id><pub-id pub-id-type="pmid">25521941</pub-id><pub-id pub-id-type="pmcid">PMC4290687</pub-id></mixed-citation></ref><ref id="pone.0330841.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brandes</surname><given-names>U</given-names></name>. <article-title>A faster algorithm for betweenness centrality</article-title>. <source>Journal of Mathematical Sociology</source>. <year>2001</year>;<volume>25</volume>(<issue>2</issue>):<fpage>163</fpage>&#8211;<lpage>77</lpage>.</mixed-citation></ref><ref id="pone.0330841.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Sprecher</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Trifonov</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gerstein</surname><given-names>M</given-names></name>. <article-title>The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics</article-title>. <source>PLoS Comput Biol</source>. <year>2007</year>;<volume>3</volume>(<issue>4</issue>):e59. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030059</pub-id><pub-id pub-id-type="pmid">17447836</pub-id><pub-id pub-id-type="pmcid">PMC1853125</pub-id></mixed-citation></ref><ref id="pone.0330841.ref035"><label>35</label><mixed-citation publication-type="book"><name name-style="western"><surname>Du</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>NH</given-names></name>, editors. <source>An efficient parallel algorithm for computing the closeness centrality in social networks. Proceedings of the 9th International Symposium on Information and Communication Technology</source>; <year>2018</year>.</mixed-citation></ref><ref id="pone.0330841.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chawla</surname><given-names>NV</given-names></name>. <article-title>Predicting node degree centrality with the node prominence profile</article-title>. <source>Sci Rep</source>. <year>2014</year>;<volume>4</volume>:<fpage>7236</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/srep07236</pub-id><pub-id pub-id-type="pmid">25429797</pub-id><pub-id pub-id-type="pmcid">PMC4246206</pub-id></mixed-citation></ref><ref id="pone.0330841.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>. <article-title>Stress detection using deep neural networks</article-title>. <source>BMC Med Inform Decis Mak</source>. <year>2020</year>;<volume>20</volume>(Suppl 11):<fpage>285</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12911-020-01299-4</pub-id><pub-id pub-id-type="pmid">33380334</pub-id><pub-id pub-id-type="pmcid">PMC7772901</pub-id></mixed-citation></ref><ref id="pone.0330841.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Hancock</surname><given-names>REW</given-names></name>. <article-title>NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data</article-title>. <source>Nat Protoc</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>823</fpage>&#8211;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nprot.2015.052</pub-id><pub-id pub-id-type="pmid">25950236</pub-id></mixed-citation></ref><ref id="pone.0330841.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Soufan</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ewald</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hancock</surname><given-names>REW</given-names></name>, <name name-style="western"><surname>Basu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>. <article-title>NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis</article-title>. <source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>(W1):W234&#8211;<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkz240</pub-id><pub-id pub-id-type="pmid">30931480</pub-id><pub-id pub-id-type="pmcid">PMC6602507</pub-id></mixed-citation></ref><ref id="pone.0330841.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Hancock</surname><given-names>REW</given-names></name>. <article-title>NetworkAnalyst--integrative approaches for protein-protein interaction network analysis and visual exploration</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>(Web Server issue):W167-74. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gku443</pub-id><pub-id pub-id-type="pmid">24861621</pub-id><pub-id pub-id-type="pmcid">PMC4086107</pub-id></mixed-citation></ref><ref id="pone.0330841.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sandelin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alkema</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Engstr&#246;m</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wasserman</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Lenhard</surname><given-names>B</given-names></name>. <article-title>JASPAR: an open-access database for eukaryotic transcription factor binding profiles</article-title>. <source>Nucleic Acids Res</source>. <year>2004</year>;<volume>32</volume>(Database issue):D91-4. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkh012</pub-id><pub-id pub-id-type="pmid">14681366</pub-id><pub-id pub-id-type="pmcid">PMC308747</pub-id></mixed-citation></ref><ref id="pone.0330841.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hsu</surname><given-names>S-D</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F-M</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>W-Y</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W-C</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>W-L</given-names></name>, <etal>et al</etal>. <article-title>miRTarBase: a database curates experimentally validated microRNA-target interactions</article-title>. <source>Nucleic Acids Res</source>. <year>2011</year>;<volume>39</volume>(Database issue):D163-9. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkq1107</pub-id><pub-id pub-id-type="pmid">21071411</pub-id><pub-id pub-id-type="pmcid">PMC3013699</pub-id></mixed-citation></ref><ref id="pone.0330841.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cannon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stevenson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Stahl</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Basu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Coffman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kiwala</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms</article-title>. <source>Nucleic Acids Res</source>. <year>2024</year>;<volume>52</volume>(D1):D1227&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkad1040</pub-id><pub-id pub-id-type="pmid">37953380</pub-id><pub-id pub-id-type="pmcid">PMC10767982</pub-id></mixed-citation></ref><ref id="pone.0330841.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hopkins</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Groom</surname><given-names>CR</given-names></name>. <article-title>The druggable genome</article-title>. <source>Nat Rev Drug Discov</source>. <year>2002</year>;<volume>1</volume>(<issue>9</issue>):<fpage>727</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrd892</pub-id><pub-id pub-id-type="pmid">12209152</pub-id></mixed-citation></ref><ref id="pone.0330841.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Russ</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Lampel</surname><given-names>S</given-names></name>. <article-title>The druggable genome: an update</article-title>. <source>Drug Discov Today</source>. <year>2005</year>;<volume>10</volume>(23&#8211;24):<fpage>1607</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1359-6446(05)03666-4</pub-id><pub-id pub-id-type="pmid">16376820</pub-id></mixed-citation></ref><ref id="pone.0330841.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zardecki</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goodsell</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Voigt</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Burley</surname><given-names>SK</given-names></name>. <article-title>RCSB Protein Data Bank: A Resource for Chemical, Biochemical, and Structural Explorations of Large and Small Biomolecules</article-title>. <source>J Chem Educ</source>. <year>2016</year>;<volume>93</volume>(<issue>3</issue>):<fpage>569</fpage>&#8211;<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jchemed.5b00404</pub-id></mixed-citation></ref><ref id="pone.0330841.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pettersen</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>EC</given-names></name>, <etal>et al</etal>. <article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>. <source>J Comput Chem</source>. <year>2004</year>;<volume>25</volume>(<issue>13</issue>):<fpage>1605</fpage>&#8211;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation></ref><ref id="pone.0330841.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schwede</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kopp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guex</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Peitsch</surname><given-names>MC</given-names></name>. <article-title>SWISS-MODEL: An automated protein homology-modeling server</article-title>. <source>Nucleic Acids Res</source>. <year>2003</year>;<volume>31</volume>(<issue>13</issue>):<fpage>3381</fpage>&#8211;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkg520</pub-id><pub-id pub-id-type="pmid">12824332</pub-id><pub-id pub-id-type="pmcid">PMC168927</pub-id></mixed-citation></ref><ref id="pone.0330841.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Olsson</surname><given-names>MHM</given-names></name>, <name name-style="western"><surname>S&#248;ndergaard</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Rostkowski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>JH</given-names></name>. <article-title>PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions</article-title>. <source>J Chem Theory Comput</source>. <year>2011</year>;<volume>7</volume>(<issue>2</issue>):<fpage>525</fpage>&#8211;<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ct100578z</pub-id><pub-id pub-id-type="pmid">26596171</pub-id></mixed-citation></ref><ref id="pone.0330841.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tzur</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title>. <source>Nucleic Acids Res</source>. <year>2008</year>;<volume>36</volume>(Database issue):D901-6. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkm958</pub-id><pub-id pub-id-type="pmid">18048412</pub-id><pub-id pub-id-type="pmcid">PMC2238889</pub-id></mixed-citation></ref><ref id="pone.0330841.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thiessen</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Bolton</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>PubChem Substance and Compound databases</article-title>. <source>Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>(D1):D1202-13. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id><pub-id pub-id-type="pmid">26400175</pub-id><pub-id pub-id-type="pmcid">PMC4702940</pub-id></mixed-citation></ref><ref id="pone.0330841.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Trott</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>AJ</given-names></name>. <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J Comput Chem</source>. <year>2010</year>;<volume>31</volume>(<issue>2</issue>):<fpage>455</fpage>&#8211;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id><pub-id pub-id-type="pmcid">PMC3041641</pub-id></mixed-citation></ref><ref id="pone.0330841.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dallakyan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>AJ</given-names></name>. <article-title>Small-molecule library screening by docking with PyRx</article-title>. <source>Methods Mol Biol</source>. <year>2015</year>;<volume>1263</volume>:<fpage>243</fpage>&#8211;<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id><pub-id pub-id-type="pmid">25618350</pub-id></mixed-citation></ref><ref id="pone.0330841.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Du</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Y-L</given-names></name>, <name name-style="western"><surname>Ai</surname><given-names>S-M</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sang</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods</article-title>. <source>Int J Mol Sci</source>. <year>2016</year>;<volume>17</volume>(<issue>2</issue>):<fpage>144</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms17020144</pub-id><pub-id pub-id-type="pmid">26821017</pub-id><pub-id pub-id-type="pmcid">PMC4783878</pub-id></mixed-citation></ref><ref id="pone.0330841.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bouysset</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fiorucci</surname><given-names>S</given-names></name>. <article-title>ProLIF: a library to encode molecular interactions as fingerprints</article-title>. <source>J Cheminform</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>72</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13321-021-00548-6</pub-id><pub-id pub-id-type="pmid">34563256</pub-id><pub-id pub-id-type="pmcid">PMC8466659</pub-id></mixed-citation></ref><ref id="pone.0330841.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weiner</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>PA</given-names></name>. <article-title>AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions</article-title>. <source>J Comput Chem</source>. <year>1981</year>;<volume>2</volume>(<issue>3</issue>):<fpage>287</fpage>&#8211;<lpage>303</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcc.540020311</pub-id></mixed-citation></ref><ref id="pone.0330841.ref057"><label>57</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ozpinar</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Peukert</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>T</given-names></name>. <article-title>An improved generalized AMBER force field (GAFF) for urea</article-title>. <source>J Mol Model</source>. <year>2010</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1427</fpage>&#8211;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00894-010-0650-7</pub-id><pub-id pub-id-type="pmid">20162312</pub-id></mixed-citation></ref><ref id="pone.0330841.ref058"><label>58</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pastor</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Szabo</surname><given-names>A</given-names></name>. <article-title>An analysis of the accuracy of Langevin and molecular dynamics algorithms</article-title>. <source>Molecular Physics</source>. <year>1988</year>;<volume>65</volume>(<issue>6</issue>):<fpage>1409</fpage>&#8211;<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00268978800101881</pub-id></mixed-citation></ref><ref id="pone.0330841.ref059"><label>59</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kr&#228;utler</surname><given-names>V</given-names></name>, <name name-style="western"><surname>van Gunsteren</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>H&#252;nenberger</surname><given-names>PH</given-names></name>. <article-title>A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations</article-title>. <source>J Comput Chem</source>. <year>2001</year>;<volume>22</volume>(<issue>5</issue>):<fpage>501</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1096-987x(20010415)22:5&amp;#x0003c;501::aid-jcc1021&amp;#x0003e;3.0.co;2-v</pub-id></mixed-citation></ref><ref id="pone.0330841.ref060"><label>60</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Genheden</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ryde</surname><given-names>U</given-names></name>. <article-title>The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities</article-title>. <source>Expert Opin Drug Discov</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>449</fpage>&#8211;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1517/17460441.2015.1032936</pub-id><pub-id pub-id-type="pmid">25835573</pub-id><pub-id pub-id-type="pmcid">PMC4487606</pub-id></mixed-citation></ref><ref id="pone.0330841.ref061"><label>61</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miller</surname><given-names>BR 3rd</given-names></name>, <name name-style="western"><surname>McGee</surname><given-names>TD Jr</given-names></name>, <name name-style="western"><surname>Swails</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Homeyer</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gohlke</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Roitberg</surname><given-names>AE</given-names></name>. <article-title>MMPBSA.py: An Efficient Program for End-State Free Energy Calculations</article-title>. <source>J Chem Theory Comput</source>. <year>2012</year>;<volume>8</volume>(<issue>9</issue>):<fpage>3314</fpage>&#8211;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/ct300418h</pub-id><pub-id pub-id-type="pmid">26605738</pub-id></mixed-citation></ref><ref id="pone.0330841.ref062"><label>62</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maruyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Igarashi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ushiku</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mitsutake</surname><given-names>A</given-names></name>. <article-title>Analysis of Protein Folding Simulation with Moving Root Mean Square Deviation</article-title>. <source>J Chem Inf Model</source>. <year>2023</year>;<volume>63</volume>(<issue>5</issue>):<fpage>1529</fpage>&#8211;<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jcim.2c01444</pub-id><pub-id pub-id-type="pmid">36821519</pub-id><pub-id pub-id-type="pmcid">PMC10015464</pub-id></mixed-citation></ref><ref id="pone.0330841.ref063"><label>63</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lobanov</surname><given-names>MYu</given-names></name>, <name name-style="western"><surname>Bogatyreva</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Galzitskaya</surname><given-names>OV</given-names></name>. <article-title>Radius of gyration as an indicator of protein structure compactness</article-title>. <source>Mol Biol</source>. <year>2008</year>;<volume>42</volume>(<issue>4</issue>):<fpage>623</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1134/s0026893308040195</pub-id><pub-id pub-id-type="pmid">18856071</pub-id></mixed-citation></ref><ref id="pone.0330841.ref064"><label>64</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munjal</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Shukla</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>TR</given-names></name>. <article-title>Chemometric approach to estimate kinetic properties of paclitaxel prodrugs and their substructures for solubility prediction through molecular modelling and simulation studies</article-title>. <source>Journal of Chemometrics</source>. <year>2019</year>;<volume>33</volume>(<issue>11</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cem.3181</pub-id></mixed-citation></ref><ref id="pone.0330841.ref065"><label>65</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Marsh</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Teichmann</surname><given-names>SA</given-names></name>. <article-title>Relative solvent accessible surface area predicts protein conformational changes upon binding</article-title>. <source>Structure</source>. <year>2011</year>;<volume>19</volume>(<issue>6</issue>):<fpage>859</fpage>&#8211;<lpage>67</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.str.2011.03.010</pub-id><pub-id pub-id-type="pmid">21645856</pub-id><pub-id pub-id-type="pmcid">PMC3145976</pub-id></mixed-citation></ref><ref id="pone.0330841.ref066"><label>66</label><mixed-citation publication-type="journal"><name name-style="western"><surname>As-Sanie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Giudice</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Gray Valbrun</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Assessing research gaps and unmet needs in endometriosis</article-title>. <source>Am J Obstet Gynecol</source>. <year>2019</year>;<volume>221</volume>(<issue>2</issue>):<fpage>86</fpage>&#8211;<lpage>94</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajog.2019.02.033</pub-id><pub-id pub-id-type="pmid">30790565</pub-id></mixed-citation></ref><ref id="pone.0330841.ref067"><label>67</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moradi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tapak</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Afshar</surname><given-names>S</given-names></name>. <article-title>Identification of Novel Noninvasive Diagnostics Biomarkers in the Parkinson&#8217;s Diseases and Improving the Disease Classification Using Support Vector Machine</article-title>. <source>Biomed Res Int</source>. <year>2022</year>;<volume>2022</volume>:<fpage>5009892</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2022/5009892</pub-id><pub-id pub-id-type="pmid">35342758</pub-id><pub-id pub-id-type="pmcid">PMC8941533</pub-id></mixed-citation></ref><ref id="pone.0330841.ref068"><label>68</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cong</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Identification and Analyzation of Differentially Expressed Transcription Factors in Endometriosis</article-title>. <source>Front Mol Biosci</source>. <year>2021</year>;<volume>7</volume>:<fpage>614427</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmolb.2020.614427</pub-id><pub-id pub-id-type="pmid">33490107</pub-id><pub-id pub-id-type="pmcid">PMC7817971</pub-id></mixed-citation></ref><ref id="pone.0330841.ref069"><label>69</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Farsimadan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Motamedifar</surname><given-names>M</given-names></name>. <article-title>The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy</article-title>. <source>Br J Biomed Sci</source>. <year>2021</year>;<volume>78</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/09674845.2020.1803540</pub-id><pub-id pub-id-type="pmid">32726192</pub-id></mixed-citation></ref><ref id="pone.0330841.ref070"><label>70</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Honda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Barrueto</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Gogusev</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Im</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Morin</surname><given-names>PJ</given-names></name>. <article-title>Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis</article-title>. <source>Reprod Biol Endocrinol</source>. <year>2008</year>;<volume>6</volume>:<fpage>59</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1477-7827-6-59</pub-id><pub-id pub-id-type="pmid">19055724</pub-id><pub-id pub-id-type="pmcid">PMC2615013</pub-id></mixed-citation></ref><ref id="pone.0330841.ref071"><label>71</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Makker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Goel</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Das</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></name>. <article-title>PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update</article-title>. <source>Gynecol Endocrinol</source>. <year>2012</year>;<volume>28</volume>(<issue>3</issue>):<fpage>175</fpage>&#8211;<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/09513590.2011.583955</pub-id><pub-id pub-id-type="pmid">21916800</pub-id></mixed-citation></ref><ref id="pone.0330841.ref072"><label>72</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>11</issue>):e0186520. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0186520</pub-id><pub-id pub-id-type="pmid">29140979</pub-id><pub-id pub-id-type="pmcid">PMC5687597</pub-id></mixed-citation></ref><ref id="pone.0330841.ref073"><label>73</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Benedito</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rocha</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Woeste</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zamykal</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Radtke</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Casanovas</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling</article-title>. <source>Nature</source>. <year>2012</year>;<volume>484</volume>(<issue>7392</issue>):<fpage>110</fpage>&#8211;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature10908</pub-id><pub-id pub-id-type="pmid">22426001</pub-id></mixed-citation></ref><ref id="pone.0330841.ref074"><label>74</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kerbel</surname><given-names>RS</given-names></name>. <article-title>Angiogenesis as a therapeutic target</article-title>. <source>Nature</source>. <year>2005</year>;<volume>438</volume>(<issue>7070</issue>):<fpage>967</fpage>&#8211;<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature04483</pub-id><pub-id pub-id-type="pmid">16355214</pub-id></mixed-citation></ref><ref id="pone.0330841.ref075"><label>75</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miettinen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rikala</surname><given-names>M-S</given-names></name>, <name name-style="western"><surname>Rys</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lasota</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z-F</given-names></name>. <article-title>Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors</article-title>. <source>Am J Surg Pathol</source>. <year>2012</year>;<volume>36</volume>(<issue>4</issue>):<fpage>629</fpage>&#8211;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/PAS.0b013e318243555b</pub-id><pub-id pub-id-type="pmid">22314185</pub-id><pub-id pub-id-type="pmcid">PMC3310951</pub-id></mixed-citation></ref><ref id="pone.0330841.ref076"><label>76</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shibuya</surname><given-names>M</given-names></name>. <article-title>Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies</article-title>. <source>Genes Cancer</source>. <year>2011</year>;<volume>2</volume>(<issue>12</issue>):<fpage>1097</fpage>&#8211;<lpage>105</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1947601911423031</pub-id><pub-id pub-id-type="pmid">22866201</pub-id><pub-id pub-id-type="pmcid">PMC3411125</pub-id></mixed-citation></ref><ref id="pone.0330841.ref077"><label>77</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Leconte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Santulli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Chouzenoux</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Marcellin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cerles</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Chapron</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis</article-title>. <source>Reprod Sci</source>. <year>2015</year>;<volume>22</volume>(<issue>9</issue>):<fpage>1171</fpage>&#8211;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1933719115592708</pub-id><pub-id pub-id-type="pmid">26169036</pub-id></mixed-citation></ref><ref id="pone.0330841.ref078"><label>78</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rahmioglu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Mortlock</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ghiasi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>M&#248;ller</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Stefansdottir</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Galarneau</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions</article-title>. <source>Nat Genet</source>. <year>2023</year>;<volume>55</volume>(<issue>3</issue>):<fpage>423</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41588-023-01323-z</pub-id><pub-id pub-id-type="pmid">36914876</pub-id><pub-id pub-id-type="pmcid">PMC10042257</pub-id></mixed-citation></ref><ref id="pone.0330841.ref079"><label>79</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xavier</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Belo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Beires</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rebelo</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Martinez-de-Oliveira</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lunet</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis</article-title>. <source>Arch Gynecol Obstet</source>. <year>2006</year>;<volume>273</volume>(<issue>4</issue>):<fpage>227</fpage>&#8211;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00404-005-0080-4</pub-id><pub-id pub-id-type="pmid">16208475</pub-id></mixed-citation></ref><ref id="pone.0330841.ref080"><label>80</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Furue</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hattori</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hosono</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tanabe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of TP signaling promotes endometriosis growth and neovascularization</article-title>. <source>Mol Med Rep</source>. <year>2023</year>;<volume>28</volume>(<issue>4</issue>):<fpage>192</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/mmr.2023.13079</pub-id><pub-id pub-id-type="pmid">37654213</pub-id><pub-id pub-id-type="pmcid">PMC10502949</pub-id></mixed-citation></ref><ref id="pone.0330841.ref081"><label>81</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bourlev</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Volkov</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Pavlovitch</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lets</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Larsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Olovsson</surname><given-names>M</given-names></name>. <article-title>The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions</article-title>. <source>Reproduction</source>. <year>2006</year>;<volume>132</volume>(<issue>3</issue>):<fpage>501</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1530/rep.1.01110</pub-id><pub-id pub-id-type="pmid">16940291</pub-id></mixed-citation></ref><ref id="pone.0330841.ref082"><label>82</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hunter</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>SA</given-names></name>. <article-title>IL-6 as a keystone cytokine in health and disease</article-title>. <source>Nat Immunol</source>. <year>2015</year>;<volume>16</volume>(<issue>5</issue>):<fpage>448</fpage>&#8211;<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ni.3153</pub-id><pub-id pub-id-type="pmid">25898198</pub-id></mixed-citation></ref><ref id="pone.0330841.ref083"><label>83</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Incognito</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Di Guardo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gulino</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Genovese</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Benvenuto</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lello</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Interleukin-6 as A Useful Predictor of Endometriosis-Associated Infertility: A Systematic Review</article-title>. <source>Int J Fertil Steril</source>. <year>2023</year>;<volume>17</volume>(<issue>4</issue>):<fpage>226</fpage>&#8211;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.22074/ijfs.2023.557683.1329</pub-id><pub-id pub-id-type="pmid">37577903</pub-id><pub-id pub-id-type="pmcid">PMC10439985</pub-id></mixed-citation></ref><ref id="pone.0330841.ref084"><label>84</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>X-M</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Z-Y</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>N</given-names></name>. <article-title>Inflammatory cytokines IL-6, IL-10, IL-13, TNF-&#945; and peritoneal fluid flora were associated with infertility in patients with endometriosis</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2018</year>;<volume>22</volume>(<issue>9</issue>):<fpage>2513</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.26355/eurrev_201805_14899</pub-id><pub-id pub-id-type="pmid">29771400</pub-id></mixed-citation></ref><ref id="pone.0330841.ref085"><label>85</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mihara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hashizume</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shiina</surname><given-names>M</given-names></name>. <article-title>IL-6/IL-6 receptor system and its role in physiological and pathological conditions</article-title>. <source>Clin Sci (Lond)</source>. <year>2012</year>;<volume>122</volume>(<issue>4</issue>):<fpage>143</fpage>&#8211;<lpage>59</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1042/CS20110340</pub-id><pub-id pub-id-type="pmid">22029668</pub-id></mixed-citation></ref><ref id="pone.0330841.ref086"><label>86</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ha</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>VN</given-names></name>. <article-title>Regulation of microRNA biogenesis</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2014</year>;<volume>15</volume>(<issue>8</issue>):<fpage>509</fpage>&#8211;<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrm3838</pub-id><pub-id pub-id-type="pmid">25027649</pub-id></mixed-citation></ref><ref id="pone.0330841.ref087"><label>87</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Begum</surname><given-names>MIA</given-names></name>, <name name-style="western"><surname>Chuan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>S-T</given-names></name>, <name name-style="western"><surname>Chae</surname><given-names>H-S</given-names></name>. <article-title>The Pathological Role of miRNAs in Endometriosis</article-title>. <source>Biomedicines</source>. <year>2023</year>;<volume>11</volume>(<issue>11</issue>):<fpage>3087</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biomedicines11113087</pub-id><pub-id pub-id-type="pmid">38002087</pub-id><pub-id pub-id-type="pmcid">PMC10669455</pub-id></mixed-citation></ref><ref id="pone.0330841.ref088"><label>88</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Daikoku</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hirota</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tranguch</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>DeMayo</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Lydon</surname><given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice</article-title>. <source>Cancer Res</source>. <year>2008</year>;<volume>68</volume>(<issue>14</issue>):<fpage>5619</fpage>&#8211;<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1274</pub-id><pub-id pub-id-type="pmid">18632614</pub-id><pub-id pub-id-type="pmcid">PMC2824329</pub-id></mixed-citation></ref><ref id="pone.0330841.ref089"><label>89</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>Y</given-names></name>. <article-title>Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1</article-title>. <source>Phytomedicine</source>. <year>2023</year>;<volume>120</volume>:<fpage>155062</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.phymed.2023.155062</pub-id><pub-id pub-id-type="pmid">37683586</pub-id></mixed-citation></ref><ref id="pone.0330841.ref090"><label>90</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chung</surname><given-names>TKH</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Yim</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>KWK</given-names></name>, <name name-style="western"><surname>Siu</surname><given-names>NSS</given-names></name>, <etal>et al</etal>. <article-title>Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1</article-title>. <source>Int J Cancer</source>. <year>2012</year>;<volume>130</volume>(<issue>5</issue>):<fpage>1036</fpage>&#8211;<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ijc.26060</pub-id><pub-id pub-id-type="pmid">21400511</pub-id></mixed-citation></ref><ref id="pone.0330841.ref091"><label>91</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>Y-Y</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>L-R</given-names></name>. <article-title>MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer</article-title>. <source>Tumour Biol</source>. <year>2016</year>;<volume>37</volume>(<issue>1</issue>):<fpage>239</fpage>&#8211;<lpage>51</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13277-015-3686-6</pub-id><pub-id pub-id-type="pmid">26198045</pub-id><pub-id pub-id-type="pmcid">PMC4841847</pub-id></mixed-citation></ref><ref id="pone.0330841.ref092"><label>92</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Elian</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Walter</surname><given-names>MA</given-names></name>. <article-title>FOXC1, the new player in the cancer sandbox</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>9</volume>(<issue>8</issue>):<fpage>8165</fpage>&#8211;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.22742</pub-id><pub-id pub-id-type="pmid">29487724</pub-id><pub-id pub-id-type="pmcid">PMC5814291</pub-id></mixed-citation></ref><ref id="pone.0330841.ref093"><label>93</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Seo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kume</surname><given-names>T</given-names></name>. <article-title>Forkhead transcription factors, Foxc1 and Foxc2, are required for the morphogenesis of the cardiac outflow tract</article-title>. <source>Dev Biol</source>. <year>2006</year>;<volume>296</volume>(<issue>2</issue>):<fpage>421</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.06.012</pub-id><pub-id pub-id-type="pmid">16839542</pub-id></mixed-citation></ref><ref id="pone.0330841.ref094"><label>94</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>S</given-names></name>. <article-title>Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue</article-title>. <source>Oncol Rep</source>. <year>2010</year>;<volume>23</volume>(<issue>3</issue>):<fpage>795</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="pmid">20127022</pub-id></mixed-citation></ref><ref id="pone.0330841.ref095"><label>95</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>C-L</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>F-C</given-names></name>, <name name-style="western"><surname>Lieblein</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Stat3 activation in human endometrial and cervical cancers</article-title>. <source>Br J Cancer</source>. <year>2007</year>;<volume>96</volume>(<issue>4</issue>):<fpage>591</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.bjc.6603597</pub-id><pub-id pub-id-type="pmid">17311011</pub-id><pub-id pub-id-type="pmcid">PMC2360038</pub-id></mixed-citation></ref><ref id="pone.0330841.ref096"><label>96</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Yoo</surname><given-names>J-Y</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>J-H</given-names></name>, <name name-style="western"><surname>Langenheim</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>SD</given-names></name>, <etal>et al</etal>. <article-title>Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis</article-title>. <source>Hum Reprod</source>. <year>2015</year>;<volume>30</volume>(<issue>5</issue>):<fpage>1069</fpage>&#8211;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/humrep/dev050</pub-id><pub-id pub-id-type="pmid">25750101</pub-id><pub-id pub-id-type="pmcid">PMC4400199</pub-id></mixed-citation></ref><ref id="pone.0330841.ref097"><label>97</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kosior</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lewandowska-Grygiel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giannopoulos</surname><given-names>K</given-names></name>. <article-title>Tyrosine kinase inhibitors in hematological malignancies</article-title>. <source>Postepy Hig Med Dosw (Online)</source>. <year>2011</year>;<volume>65</volume>:<fpage>819</fpage>&#8211;<lpage>28</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5604/17322693.968778</pub-id><pub-id pub-id-type="pmid">22173446</pub-id></mixed-citation></ref><ref id="pone.0330841.ref098"><label>98</label><mixed-citation publication-type="journal"><name name-style="western"><surname>O&#8217;Hare</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shakespeare</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Eide</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</article-title>. <source>Cancer Cell</source>. <year>2009</year>;<volume>16</volume>(<issue>5</issue>):<fpage>401</fpage>&#8211;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ccr.2009.09.028</pub-id><pub-id pub-id-type="pmid">19878872</pub-id><pub-id pub-id-type="pmcid">PMC2804470</pub-id></mixed-citation></ref><ref id="pone.0330841.ref099"><label>99</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoshino</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Osuga</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hirota</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Koga</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hirata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Harada</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis</article-title>. <source>Am J Reprod Immunol</source>. <year>2004</year>;<volume>52</volume>(<issue>5</issue>):<fpage>306</fpage>&#8211;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1600-0897.2004.00231.x</pub-id><pub-id pub-id-type="pmid">15550066</pub-id></mixed-citation></ref><ref id="pone.0330841.ref100"><label>100</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ng&#244;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nicco</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leconte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ch&#233;reau</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Arkwright</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vacher-Lavenu</surname><given-names>M-C</given-names></name>, <etal>et al</etal>. <article-title>Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo</article-title>. <source>J Pathol</source>. <year>2010</year>;<volume>222</volume>(<issue>2</issue>):<fpage>148</fpage>&#8211;<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/path.2756</pub-id><pub-id pub-id-type="pmid">20821752</pub-id></mixed-citation></ref><ref id="pone.0330841.ref101"><label>101</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Driva</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Schatz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haybaeck</surname><given-names>J</given-names></name>. <article-title>Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis</article-title>. <source>Biomolecules</source>. <year>2023</year>;<volume>13</volume>(<issue>8</issue>):<fpage>1253</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biom13081253</pub-id><pub-id pub-id-type="pmid">37627318</pub-id><pub-id pub-id-type="pmcid">PMC10452661</pub-id></mixed-citation></ref><ref id="pone.0330841.ref102"><label>102</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reva</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Finkelstein</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Skolnick</surname><given-names>J</given-names></name>. <article-title>What is the probability of a chance prediction of a protein structure with an rmsd of 6 A?</article-title>. <source>Fold Des</source>. <year>1998</year>;<volume>3</volume>(<issue>2</issue>):<fpage>141</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1359-0278(98)00019-4</pub-id><pub-id pub-id-type="pmid">9565758</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>